



20-11-2020

11:00 - 11:45 **Type: Opening session** **Channel 1**
Title: Opening session and Keynote address - Beyond immune checkpoint blockade: Emerging strategies

Chair: Solange Peters, CH; Enriqueta Felip, ES; Takayuki Yoshino, JP; Florian Lordick, DE; Anthony T.C. Chan, HK

11:00 - 11:20 **Opening session**

S. Peters¹, E. Felip², T. Yoshino³, F. Lordick⁴, A.T.C. Chan⁵, ¹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ²Vall d'Hebron University Hospital, Barcelona, ES, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Universitätsklinikum Leipzig, Leipzig, DE, ⁵The Chinese University of Hong Kong, Sha Tin, HK

11:20 - 11:45 **Beyond immune checkpoint blockade: Emerging strategies**

T. Mak, Princess Margaret Cancer Center, Toronto, CA



12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 1**
Title: AstraZeneca - Improving outcomes with immuno-oncology: Evolving treatment paradigms for first-line ES-SCLC and unresectable Stage III NSCLC
 Chair: Martin Reck, DE

12:00 - 12:06 **Welcome and introduction**
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

12:06 - 12:18 **Emerging immuno-oncology treatment strategies for first-line ES-SCLC**
M.-J. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

12:18 - 12:33 **Treating ES-SCLC using immuno-oncology: A clinical case study**
M.-J. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

12:33 - 12:45 **The treatment paradigm for unresectable stage III NSCLC: recent clinical advances with immuno-oncology**
Y.-L. Wu, Guangdong Lung Cancer Institute, Guangzhou, CN

12:45 - 13:00 **Treating unresectable Stage III NSCLC using immuno-oncology: A clinical case study**
Y.-L. Wu, Guangdong Lung Cancer Institute, Guangzhou, CN

13:00 - 13:30 **Audience Q&A**
M. Reck¹, M.-J. Ahn², Y.-L. Wu³, ¹Krankenhaus Grosshansdorf, Grosshansdorf, DE, ²Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ³Guangdong Lung Cancer Institute, Guangzhou, CN

12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 2**
Title: Bristol Myers Squibb - The role of immuno-oncology in the evolving treatment landscapes of upper GI cancers
 Chair: Matthew Ng, SG

12:00 - 13:15 **The role of immuno-oncology in the evolving treatment landscapes of upper GI cancers**
M. Ng¹, K. Shitara², C.-H. Hsu³, K.-O. Lam⁴, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²National Cancer Center Hospital East, Kashiwa, JP, ³National Taiwan University Cancer Center, Taipei, TW, ⁴The University of Hong Kong, Hong Kong, CN

13:15 - 13:30 **Live Q&A**
M. Ng¹, K. Shitara², C.-H. Hsu³, K.-O. Lam⁴, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²National Cancer Center Hospital East, Kashiwa, JP, ³National Taiwan University Cancer Center, Taipei, TW, ⁴The University of Hong Kong, Hong Kong, CN



12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 3**
Title: MSD - Extending Longer-Term Survival in Lung Cancer and HNSCC with IO and Novel Combinations
 Chair: Daniel Shao Weng Tan, SG

12:00 - 13:15 **Extending Longer-Term Survival in Lung Cancer and HNSCC with IO and Novel Combinations**
D.S.W. Tan¹, R. Hui², E. Cohen³, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Westmead Hospital and the University of Sydney, Sydney, AU, ³Moore's Cancer Center - UC San Diego Health, La Jolla, US

13:15 - 13:30 **Q&A and Closing**
D.S.W. Tan¹, R. Hui², E. Cohen³, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Westmead Hospital and the University of Sydney, Sydney, AU, ³Moore's Cancer Center - UC San Diego Health, La Jolla, US

12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 4**
Title: Daiichi Sankyo - Expanding the horizon for the treatment of solid tumors with antibody drug conjugates (ADCs)
 Chair: Tony S.K. Mok, HK

12:00 - 12:05 **Welcome and introduction**
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

12:05 - 12:20 **How are technologically advanced ADCs expanding the horizon for the treatment of solid tumours?**
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

12:20 - 12:40 **Expanding the horizon for the treatment of breast cancer with ADCs**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

12:40 - 12:55 **Expanding the horizon for the treatment of lung cancer with ADCs**
K. Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR

12:55 - 13:15 **Expanding the horizon for the treatment of colorectal and gastric cancer with ADCs**
H.C. Chung, Severance Hospital, Seoul, KR

13:15 - 13:30 **Live Q&A + summary and close**
T.S.K. Mok¹, R. Dent², K. Park³, H.C. Chung⁴, ¹Prince of Wales Hospital, Shatin, HK, ²NCCS - National Cancer Centre Singapore, Singapore, SG, ³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Severance Hospital, Seoul, KR



12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 5**
Title: Pfizer - Clinical Evidence to Real-World Experience: Bridging the Best of Both Worlds in the Management of ER+ HER2- mBC
 Chair: Adam Brufsky, US

12:00 - 12:05 **Introductory note**
T. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

12:05 - 12:35 **Optimizing patient care in HR+/HER2- mBC in present times**
A. Brufsky, Magee-Womens Hospital of UPMC, Pittsburgh, US

12:35 - 13:05 **Real-world evidence of palbociclib & treatment approach in Asian patients**
S. Dawood, Dubai Hospital Pacemaker and EP Clinics, Dubai, AE

13:05 - 13:30 **Q&A and closing**
A. Brufsky¹, S. Dawood², T. Tan³, ¹Magee-Womens Hospital of UPMC, Pittsburgh, US, ²Dubai Hospital Pacemaker and EP Clinics, Dubai, AE, ³NCCS - National Cancer Centre Singapore, Singapore, SG

12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 6**
Title: Merck Pfizer Alliance - New developments in mUC and mRCC: The year 2020 in review
 Chair: Joaquim Bellmunt, US

12:00 - 12:05 **Introduction**
J. Bellmunt, Harvard Medical School, Boston, US

12:05 - 12:25 **Milestones in 2020: key data from first-line mUC trials**
P. Grivas, University of Washington; Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance, Seattle, US

12:25 - 12:45 **From data to clinical practice: today's data in tomorrow's management of mUC**
J. Bellmunt, Harvard Medical School, Boston, US

12:45 - 13:05 **Individualizing systemic therapy in mRCC**
H. Gurney, The Crown Princess Mary Cancer Centre, Westmead, AU



14:00 - 15:20 **Type: Educational session** **Channel 1**
Title: Challenges for molecularly-driven diseases in 2020
 Chair: Pilar Garrido Lopez, ES; Yi-Long Wu, CN

14:00 - 14:20 **EGFR mutations: How to anticipate, identify and target the resistances to third generation EGFR TKI**
Y.-L. Wu, Guangdong Lung Cancer Institute, Guangzhou, CN

14:20 - 14:40 **ALK: How to improve on the current standard?**
B. Solomon, Peter MacCallum Cancer Center, Melbourne, AU

14:40 - 15:00 **KRAS: The untargetable target finally defeated?**
P. Jänne, Dana Farber Cancer Institute, Boston, US

15:00 - 15:15 **LIVE Q&A**

14:00 - 15:20 **Type: Educational session** **Channel 2**
Title: Biomarkers in the management of colorectal cancer
 Chair: Julien Taieb, FR; Jeanne Tie, AU

14:00 - 14:20 **Targeting BRAF, MSI and beyond in metastatic colorectal cancer**
G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE

14:20 - 14:40 **Molecular profiling for metastatic colorectal cancer: Who, when and how?**
C. Montagut Viladot, Hospital del Mar, Barcelona, ES

14:40 - 15:00 **Can ctDNA turn the tide for adjuvant treatment in colon cancer?**
J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU

15:00 - 15:15 **LIVE Q&A**



14:00 - 15:20 **Type: Educational session** **Channel 3**
Title: Therapeutic decisions in the adjuvant setting of melanoma
 Chair: Paul Lorigan, GB; Alexander van Akkooi, NL

14:00 - 14:15 **What is the role of surgery in the modern management of stage III melanoma**
A. Van Akkooi, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:15 - 14:30 **Targeted therapies in the adjuvant setting**
A. Hauschild, UK-SH, Campus Kiel, Kiel, DE

14:30 - 14:45 **Immunotherapies in the adjuvant setting**
P. Lorigan, The Christie NHS Foundation Trust, Manchester, GB

14:45 - 15:00 **Adjuvant treatments for mucosal melanoma? What should we do?**
J.W.-C. Chang, Chang Gung Medical Foundation-Linkou, Taoyuan, TW

15:00 - 15:15 **LIVE Q&A**

14:00 - 15:20 **Type: Collaborative session** **Channel 4**
Title: Optimizing health care systems: Sustainability, accessibility, excellence (in collaboration with KSMO)
 Chair: Josep Tabernero, ES; Young Suk Park, KR

14:00 - 14:15 **Building networks of reference centers of excellence in Korea and comparison to the ERN paradigm**
Y.S. Park, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

14:15 - 14:30 **The role and value of biosimilars in a modern health care systems**
J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

14:30 - 14:45 **How to validate, position and link real world data in the context of a learning health care system**
K. Chan, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA

14:45 - 15:00 **Community cancer care model in Rural area: A Korean model for integration of Regional and public health care center**
J.H. Kang, Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, Jinju, KR

15:00 - 15:20 **Live Q&A and live discussion**



14:00 - 15:20 **Type: Special Session** **Channel 5**
Title: Contemporary combination strategies of radiotherapy in the multidisciplinary management of advanced cancers
 Chair: Françoise Mornex, FR; Melvin Lee Kiang Chua, SG; Yong Chan Ahn, KR

14:00 - 14:15 **How to optimise surgery, chemotherapy and radiotherapy for bladder preservation in muscle invasive bladder cancer**
M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

14:15 - 14:30 **H&N carcinoma: State of the art of the combination IO and radiation**
K. Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

14:30 - 14:45 **Oligometastases: State of the art of the combination IO and radiation**
S. Siva, Peter MacCallum Cancer Centre, Melbourne, AU

14:45 - 15:00 **NSCLC: IO and radiation, state of the art**
D. De Ruyscher, Maastrro Clinic, Maastricht, NL

15:00 - 15:20 **LIVE Q&A**

15:35 - 16:55 **Type: Educational session** **Channel 1**
Title: What are the most exciting new developments in immunotherapy of cancer?
 Chair: John Haanen, NL; Shigehisa Kitano, JP

15:35 - 15:50 **Neoadjuvant immunotherapy: Why does it work better?**
J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

15:50 - 16:05 **CAR-T in solid cancer: What are the hurdles?**
S. Kitano, National Cancer Center Hospital, Tokyo, JP

16:05 - 16:20 **Combining immunotherapy and angiogenesis inhibition: Is there synergy?**
S. Peters, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

16:20 - 16:35 **Intratumoral immunotherapy: For whom?**
J. Cebon, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU

16:35 - 16:50 **LIVE Q&A**



15:35 - 16:55 **Type: Educational session** **Channel 2**
Title: Optimal treatment of prostate cancer in changing times
 Chair: Ravindran Kanesvaran, SG; Silke Gillessen, CH

15:35 - 15:55 **State-of-the-art management of metastatic hormone-sensitive prostate cancer (mHSPC)**
K. Fizazi, Institut Gustave Roussy, Villejuif, FR

15:55 - 16:15 **Metastatic castration-resistant prostate (mCRPC) cancer updates**
S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

16:15 - 16:35 **Ethnic differences (pharmacogenomic differences in Asian patients) in the management of metastatic prostate cancer**
M.C. Poon, The Chinese University of Hong Kong, Sha Tin, HK

16:35 - 16:50 **LIVE Q&A**

15:35 - 16:55 **Type: Educational session** **Channel 3**
Title: Precision oncology: Genomics and beyond
 Chair: Hiroya Taniguchi, JP; Charlotte Ng, CH

15:35 - 15:55 **Mutational signatures: Predictive value across tumor types**
X. Zou, University of Cambridge, Cambridge, GB

15:55 - 16:15 **Translating cancer evolution into clinical management**
H. Taniguchi, National Cancer Center Hospital East, Kashiwa, JP

16:15 - 16:35 **Personalized in vitro and in vivo cancer models to guide precision medicine**
A. Bruna, ICR - Institute of Cancer Research, London, GB

16:35 - 16:50 **LIVE Q&A**



15:35 - 16:55	Type: Collaborative session Title: Gastric cancer in Asia Pacific and the West (in collaboration with JSMO)	Channel 4
	Chair: Andres Cervantes, ES; Kohei Shitara, JP	
15:35 - 15:50	Distinct biology of gastric cancer in Asian versus non-Asian populations: Perception or reality? <u>H. Van Laarhoven</u> , University of Amsterdam, Cancer Center Amsterdam, Amsterdam Medical Centers, Amsterdam, NL	
15:50 - 16:05	Programs of primary and secondary prevention for gastric cancer in Japan: Utility and cost <u>M. Inoue</u> , NCCH - National Cancer Center Hospital, Chuo-ku, JP	
16:05 - 16:20	Management of localised gastric cancer: Emphasis on regional or systemic approaches? <u>K. Shitara</u> , National Cancer Center Hospital East, Kashiwa, JP	
16:20 - 16:35	New perspectives in systemic therapies of advanced gastric cancer <u>T. Götze</u> , Nordwest-Krankenhaus, Frankfurt am Main, DE	
16:35 - 16:55	Live Q&A and live discussion	



15:35 - 16:55	<p>Type: Educational session Title: Cancer policy in the Asia-Pacific region: How to successfully advocate for access to care and research Chair: Rosa Giuliani, GB; Bhawna Sirohi, IN</p>	<p>Channel 5</p>
15:35 - 15:38	Live introduction	
15:38 - 15:53	<p>Cancer Policy 101: Setting the scene R. Giuliani, The Clatterbridge Cancer Centre, Liverpool, GB</p>	
15:53 - 16:08	<p>How ESMO successfully advocated towards protecting health research at the EU level: The General Data Protection Regulation (GDPR) story P.G. Casali, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT</p>	
16:08 - 16:23	<p>Access to high quality and sustainable care in the Asia-Pacific region: The perspective of HTA L. Loke, ACE - Agency for Care Effectiveness - Ministry of Health, Singapore, SG</p>	
16:23 - 16:38	<p>The importance of involving patients in policy making in China J. Zhang, House086(Lymphoma Association of China), Beijing, CN</p>	
16:38 - 16:50	LIVE Q&A	



17:10 - 18:30 **Type: Educational session** **Channel 1**
Title: Are large NGS panels really changing patient outcomes?
 Chair: Myung-Ju Ahn, KR; Wen-Zhao Zhong, CN

17:10 - 17:25 **Several potential new targets are missed regarding current guidelines**
F. Barlesi, Gustave Roussy - Cancer Campus, Villejuif, FR

17:25 - 17:40 **Are the addition of these new targets really changing patient outcomes globally?**
J. Wolf, Uniklinik Köln, Cologne, DE

17:40 - 17:55 **Designing a pragmatic strategy for adequately genotyping advanced NSCLC**
M.-J. Ahn, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR

17:55 - 18:10 **Immunotherapy biomarkers: What should we be prepared to assess beyond PDL1?**
C. Zhou, Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN

18:10 - 18:25 **LIVE Q&A**

17:10 - 18:30 **Type: Educational session** **Channel 2**
Title: Genetic testing for hereditary breast cancer and therapeutic implications
 Chair: Fatima Cardoso, PT; Veronique Tan, SG

17:10 - 17:25 **A Geneticist's point of view**
J. Ngeow, Cleveland Clinic, Cleveland, US

17:25 - 17:40 **Surgeon point of view**
S. Nakamura, Showa University Hospital, Shinagawa-ku, JP

17:40 - 17:55 **A Medical oncologist's point of view**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

17:55 - 18:10 **A Radiation oncologist's point of view**
B. Chua, Prince of Wales Hospital - Nelune Comprehensive Cancer Centre, Randwick, AU

18:10 - 18:25 **LIVE Q&A**



17:10 - 18:30 **Type: Educational session** **Channel 3**
Title: Side effect management of old and new anti-tumour agents: ESMO Guidelines into practice
 Chair: Alexandre Chan, US; Karin Jordan, DE

17:10 - 17:30 **Checkpoint inhibitors: How to manage rare and life threatening irAE**
C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

17:30 - 17:50 **Acute toxicity: Side-effect management of conventional chemotherapeutic agents**
F. Scotté, Institut Gustave Roussy, Villejuif, FR

17:50 - 18:10 **Updates in oncological emergencies**
A. Chan, University of California, Irvine School of Medicine, Irvine, US

18:10 - 18:25 **LIVE Q&A**

17:10 - 18:30 **Type: Collaborative session** **Channel 4**
Title: Innovation in oncology drug development and regulation (in collaboration with CSCO)
 Chair: Solange Peters, CH; Rui-Hua Xu, CN

17:10 - 17:25 **Acral and mucosal melanoma: On the road**
J. Guo, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN

17:25 - 17:40 **Novel clinical trial designs**
U. Dafni, University of Athens, Athens, GR

17:40 - 17:55 **Bottleneck, coping strategy and expectation: Anti-angiogenic therapy in China**
K. Li, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN

17:55 - 18:10 **Registration-class real world evidence for oncology drug approval: Utopia or promise?**
M. Koopman, University Medical Center Utrecht, Utrecht, NL

18:10 - 18:30 **Live Q&A and live discussion**



17:10 - 18:30 **Type: Collaborative session** **Channel 5**
Title: Hopes and limitations for CRISPR technology in cancer (in collaboration with AACR)
 Chair: Alex A. Adjei, US; Michel Sadelain, US

17:10 - 17:12 **Open and welcome**

A.A. Adjei, Mayo Clinic, Rochester, US

17:12 - 17:31 **CRISPR as a tool for rational design of drug combinations**

R. Bernards, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

17:31 - 17:50 **CRISPR in the Clinic: CRISPR-edited T cells for lung cancer therapy**

Y. Lu, West China Hospital, Chengdu, CN

17:50 - 18:09 **CRISPR-edited CAR T cells**

M. Sadelain, Memorial Sloan Kettering Cancer Center, New York, US

18:09 - 18:28 **CRISPR screens identify novel targets regulating tumor immune microenvironment**

X.S. Liu, Dana Farber Cancer Institute, Boston, US

18:28 - 18:30 **Conclusion**

M. Sadelain, Memorial Sloan Kettering Cancer Center, New York, US

18:45 - 20:00 **Type: Mini Oral session** **Channel 1**
Title: Mini oral session on Gastrointestinal tumours 1
 Chair: Li-Tzong Chen, TW

18:45 - 18:50 **115MO - Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib: NAVIGATOR phase I trial update**

Y.-K. Kang¹, R. Jones², M. Von Mehren³, C. Serrano⁴, S. George⁵, M.C. Heinrich⁶, P. Schöffski⁷, O. Mir⁸, P. Cassier⁹, F. Eskens¹⁰, P. Rutkowski¹¹, W. Tap¹², S. Chawla¹³, H. Shi¹⁴, M. Roche¹⁴, S. Bauer¹⁵, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Royal Marsden Hospital and Institute of Cancer Research, London, GB, ³Fox Chase Cancer Center, Philadelphia, US, ⁴Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁵Dana-Farber Cancer Institute, Boston, US, ⁶Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, US, ⁷University Hospitals Leuven, Leuven Cancer Institute, Leuven, BE, ⁸Institut Gustave Roussy, Villejuif, FR, ⁹Centre Léon Bérard, Lyon, FR, ¹⁰Erasmus MC Cancer Institute, Rotterdam, NL, ¹¹Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ¹²Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, ¹³Sarcoma Oncology Center, Santa Monica, US, ¹⁴Blueprint Medicines Corporation, Cambridge, US, ¹⁵University of Duisburg-Essen, Essen, DE



- 18:50 - 18:55 **116MO - Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2**
J. Furuse¹, L. Goyal², F. Meric-Bernstam³, A. Hollebecque⁴, J. Valle⁵, C. Morizane⁶, T. Karasic⁷, T. Abrams⁸, R. Kelley⁹, P. Cassier¹⁰, H.-J. Klumpen¹¹, N. Uboha¹², A. Mahipal¹³, E. Mitchell¹⁴, E. Ahn¹⁵, H.-M. Chang¹⁶, K. Masuda¹⁷, Y. He¹⁸, K. Benhadji¹⁸, J. Bridgewater¹⁹, ¹Kyorin university Hospital, Tokyo, JP, ²Massachusetts General Hospital, Boston, US, ³The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁴Institut Gustave Roussy, Paris, FR, ⁵University of Manchester, Manchester, GB, ⁶National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP, ⁷Hospital of the University of Pennsylvania, Philadelphia, US, ⁸Dana-Farber Cancer Institute, Boston, US, ⁹UCSF, San Francisco, US, ¹⁰Centre Léon Bérard, Lyon, FR, ¹¹Amsterdam University Medical Centers, Amsterdam, NL, ¹²University of Wisconsin, Madison, US, ¹³Mayo Clinic Rochester, Rochester, US, ¹⁴Sidney Kimmel Cancer Center at Jefferson, Philadelphia, US, ¹⁵Cancer Treatment Centers of America, Chicago, US, ¹⁶Asan Medical Center, Seoul, KR, ¹⁷Tohoku University, Sendai, JP, ¹⁸Taiho Oncology, New York, US, ¹⁹UCL Cancer Institute, London, GB
- 18:55 - 19:00 **117MO - Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed adenoneuroendocrine carcinoma and adenocarcinoma: A multicenter study from China**
J.-P. Lin, G.-J. Lin, Z.-K. Wang, J.-X. Lin, C.-H. Zheng, P. Li, J.-W. Xie, J.-B. Wang, J. Lu, Q.-Y. Chen, L.-L. Cao, M. Lin, R.-H. Tu, Z.-N. Huang, J.-L. Lin, H.-L. Zheng, C. Huang, Fujian Medical University Union Hospital, Fuzhou, CN
- 19:00 - 19:05 **118MO - Circulating tumour DNA methylation are markers for early detection of pancreatic ductal adenocarcinoma (PDAC)**
X. Liu¹, Q. He², Z. Liang¹, H. Wu¹, Y. Li¹, Z. Zhang¹, L. Yu¹, M. Dai¹, S. Guo³, G. Jin⁴, S. Shen⁴, Z. Su², C. Ma², Z. Xie², R. Liu², ¹PUMCH-Peking Union Medical College Hospital (East), Beijing, CN, ²Singlera Genomics Inc., Shanghai, CN, ³Changhai Hospital, Second Military Medical University, Shanghai, CN, ⁴Changhai Hospital, Second Military Medical University, Shanghai, CN
- 19:05 - 19:15 **Invited Discussant abstracts 115MO, 116MO, 117MO and 118MO**
D. Tai, NCCS - National Cancer Centre Singapore, Singapore, SG
- 19:15 - 19:25 **LIVE Q&A**
- 19:25 - 19:30 **119MO - Application of an artificial neural network for predicting the chemotherapy benefit of patients with gastric cancer after radical surgery**
Z. Xue, D. Wu, L.-L. Shen, J. Lu, C.-H. Zheng, P. Li, J.-W. Xie, J.-B. Wang, J.-X. Lin, Q.-Y. Chen, L.-L. Cao, M. Lin, R.-H. Tu, Z.-N. Huang, J.-L. Lin, H.-L. Zheng, C. Huang, Fujian Medical University Union Hospital, Fuzhou, CN
- 19:30 - 19:35 **120MO - A phase II study of trifluridine/tipiracil and ramucirumab in patients with unresectable advanced or recurrent gastric cancer**



T. Ando¹, A. Kawazoe², H. Hosaka³, J. Fujita⁴, K. Koeda⁵, K. Nishikawa⁶, K. Amagai⁷, K. Fujitani⁸, K. Ogata⁹, Y. Yamamoto⁹, K. Shitara², ¹Toyama University Hospital, Toyama, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³Gunma Prefectural Cancer Center, Ota, JP, ⁴Sakai City Medical Center, Sakai, JP, ⁵Iwate Medical University Hospital, Shiwa, JP, ⁶National Hospital Organization Osaka National Hospital, Osaka, JP, ⁷Ibaraki Prefectural Central Hospital, Kasama, JP, ⁸Osaka General Medical Center, Osaka, JP, ⁹Taiho Pharmaceutical Co. Ltd, Tokyo, JP

19:35 - 19:40 **121MO - ctDNA and prognosis in resected esophageal adenocarcinoma (EAC)**

E. Ococks¹, A. Frankell², N. Masque Soler², A. Northrop², H. Coles², N. Grehan², A. Redmond², C. Hughes³, G. Devonshire², A. Blasko², O. Oesophageal Cancer Clinical And Molecular Stratification Consortium², R. Fitzgerald², E. Smyth², ¹MRC Cancer Unit, Hutchison/MRC Research Centre, Cambridge, GB, ²University of Cambridge, Cambridge, GB, ³Addenbrooke's Hospital, Cambridge, GB

19:40 - 19:48 **Invited Discussant abstracts 119MO, 120MO and 121MO**

D.-Y. Oh, Seoul National University Hospital, Seoul, KR

19:48 - 19:56 **LIVE Q&A**

18:45 - 20:20 Type: Mini Oral session Channel 2
Title: Mini oral session on Breast cancer
 Chair: Smruti Koppikar, IN

18:45 - 18:50 **2MO - Abemaciclib in high risk early breast cancer**

S. Johnston¹, N. Harbeck², R. Hegg³, M. Toi⁴, M. Martin⁵, Z. Shao⁶, M. Campone⁷, E. Hamilton⁸, J. Sohn⁹, V. Guarneri¹⁰, J. Cortes¹¹, P. Neven¹², F. Boyle¹³, I. Smith¹⁴, M. Frenzel¹⁵, D. Headley¹⁴, R. Wei¹⁴, J. Cox¹⁴, J. O'Shaughnessy¹⁶, P. Rastogi¹⁷, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²LMU University Hospital, Munich, DE, ³Gynecological Clinical Service School of Medicine, Univ. Sao Paulo, Sao Paulo, BR, ⁴Kyoto University Hospital, Kyoto, JP, ⁵Hospital General Universitario Gregorio Marañon, Madrid, ES, ⁶Fudan University Shanghai Cancer Center, Shanghai, CN, ⁷ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁸Sarah Cannon Research Institute, Nashville, US, ⁹Yonsei University, Seoul, KR, ¹⁰Istituto Oncologico Veneto IRCCS, Padova, IT, ¹¹IOB Institute of Oncology, Barcelona, ES, ¹²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹³Mater Hospital, North Sydney, North Sydney, AU, ¹⁴Eli Lilly and Company, Indianapolis, US, ¹⁵Eli Lilly and Company - Global Headquarters, Indianapolis, US, ¹⁶Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ¹⁷NSABP Foundation, Pittsburgh, US

18:50 - 18:55 **LBA1 - Baseline characteristics of patients from Asia enrolled in monarchE, evaluating abemaciclib in high risk early breast cancer**

Z. Jiang¹, T. Nakayama², S. Nakamura³, S.-C. Lee⁴, S.-C. Chen⁵, J. Feng⁶, J.H. Tang⁷, M. Saito⁸, Y. Miyoshi⁹, C.-L. Liu¹⁰, H.K. Ahn¹¹, S. Sherwood¹², A. Zimmermann¹³, J. Cox¹³, I.H. Park¹⁴, ¹The Fifth Medical Center of PLA General Hospital, Beijing, CN, ²Osaka International Cancer Institute, Osaka, JP, ³Showa University Hospital, Tokyo, JP,



⁴National University Hospital, Singapore, SG, ⁵Chang Gung Memorial Hospital - Linkou, Taoyuan, TW, ⁶Jiangsu Cancer Hospital, Jiangsu Province, CN, ⁷Jiangsu Province Hospital, Nanjing, CN, ⁸Juntendo University Hospital, Tokyo, JP, ⁹Hyogo College of Medicine, Hyogo, JP, ¹⁰MacKay Memorial Hospital, Taipei City, TW, ¹¹Gachon University Gil Medical Center, Incheon, KR, ¹²Eli Lilly Australia, West Ryde, AU, ¹³Eli Lilly and Company, Indianapolis, US, ¹⁴Center for Breast Cancer, National Cancer Center, Goyang, KR

18:55 - 19:00

47MO - Efficacy and quality of life (QOL) in premenopausal Asian patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) treated in the MONALEESA (ML)-7 study

Y.-S. Lu¹, J. Sohn², K.S. Lee³, K.H. Jung⁴, G. Babu⁵, M.-C. Liu⁶, V. Srimuninnimit⁷, Y.S. Yap⁸, L. Chow⁹, A. Gaur¹⁰, Y. Wang¹¹, M. Gao¹², S.-A. Im¹³, ¹National Taiwan University Hospital, Taipei, TW, ²Yonsei University Health System, Seoul, KR, ³National Cancer Center, Goyang, KR, ⁴University of Ulsan College of Medicine, Seoul, KR, ⁵HCG Curie Centre of Oncology and Kidwai Memorial Institute of Oncology, Bangalore, IN, ⁶Foundation Sun Yat-Sen Cancer Center, Taipei, TW, ⁷Siriraj Hospital, Mahidol University, Bangkok, TH, ⁸National Cancer Centre Singapore, Singapore, SG, ⁹Organisation for Oncology and Translational Research, Hong Kong, HK, ¹⁰Novartis Healthcare Pvt Ltd, Hyderabad, IN, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, US, ¹²Novartis Pharmaceuticals AG, Basel, CH, ¹³Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR

19:00 - 19:05

48MO - Ribociclib (RIB) + letrozole (LET) in Asian patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompleEment-1 trial

S. Chatterjee¹, M. Md Yusof², T. Dejthevaporn³, W.-P. Chung⁴, C. Galvez⁵, P. Sunpaweravong⁶, A. Cheng⁷, M.L. Abesamis-Tiambeng⁸, S.O.Y. Michelle⁹, L. Menon-Singh¹⁰, J. Wu¹¹, K. Zhou¹¹, H. Azim¹², ¹TMC - Tata Medical Center, Kolkata, IN, ²Pantai Medical Centre, Kuala Lumpur, MY, ³Ramathibodi Hospital, Mahidol University, Bangkok, TH, ⁴National Cheng Kung University Hospital, College of Medicine, Tainan City, TW, ⁵Veterans Memorial Medical Center St. Luke's Medical Center - Global City, Metro Manila, PH, ⁶Prince of Songkla University, Songkhla, TH, ⁷Princess Margaret Hospital, Kwai Chung, HK, ⁸Cardinal Santos Medical Center, Metro Manila, PH, ⁹Queen Elizabeth Hospital, Yau Ma Tei, HK, ¹⁰Novartis Pharmaceuticals, East Hanover, US, ¹¹Novartis Pharmaceuticals, East Hanover, NJ, US, ¹²Faculty of Medicine, Cairo University, Cairo, EG

19:05 - 19:15

Invited Discussant abstracts 2MO, LBA1, 47MO and 48MO

S. Saji, Fukushima Medical University, Fukushima, JP

19:15 - 19:25

LIVE Q&A

19:25 - 19:30

3MO - IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemo in early triple-negative breast cancer (TNBC)

S. Saji¹, E. Mittendorf², N. Harbeck³, H. Zhang⁴, C.H. Barrios⁵, R. Hegg⁶, A. Koehler⁷, J.



Sohn⁸, H. Iwata⁹, M. Telli¹⁰, C. Ferrario¹¹, K. Punie¹², F. Penault Llorca¹³, S. Patel¹⁴, A. Nguyen Duc¹⁵, M. Liste Hermoso¹⁶, V. Maiya¹⁷, L. Molinero¹⁷, S. Chui¹⁸, K.H. Jung¹⁹,
¹Fukushima Medical University, Fukushima, JP, ²Brigham and Women's Hospital, Boston, US, ³Ludwig Maximilians University - Grosshadern, Munich, DE, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵Centro de Pesquisa em Oncologia, HSL, PUCRS, Porto Alegre, BR, ⁶Gynecological Clinical Service School of Medicine, Univ. Sao Paulo, Sao Paulo, BR, ⁷Onkologie Schwerpunktpraxis, Langen (Hessen), DE, ⁸Yonsei University Health System, Seoul, KR, ⁹Aichi Cancer Center Hospital, Nagoya, JP, ¹⁰Stanford University, Stanford, US, ¹¹Jewish General Hospital McGill University, Montreal, CA, ¹²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹³Centre Jean Perrin, Clermont-Ferrand, FR, ¹⁴F Hoffman Roche, San Francisco, US, ¹⁵F Hoffman Roche, Basel, CH, ¹⁶F. Hoffmann-La Roche, Ltd., Basel, CH, ¹⁷Genentech, Inc. - Member of the Roche Group, South San Francisco, US, ¹⁸Genentech, Inc., South San Francisco, US, ¹⁹University of Ulsan College of Medicine, Seoul, KR

19:30 - 19:35 **49MO - IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer**

H. Iwata¹, L. Emens², S. Adams³, C. Barrios⁴, V. Diéras⁵, S. Loi⁶, H. Rugo⁷, A. Schneeweiss⁸, E. Winer⁹, S. Patel¹⁰, V. Henschel¹¹, A. Swat¹¹, M. Kaul¹⁰, L. Molinero¹², S. Chui¹⁰, P. Schmid¹³, ¹Aichi Cancer Center Hospital, Nagoya, JP, ²University of Pittsburgh Medical Center, Pittsburgh, US, ³New York University Langone Health, New York, US, ⁴PUCRS, Porto Alegre, BR, ⁵Centre Eugène Marquis, Rennes, FR, ⁶Peter MacCallum Cancer Centre, Melbourne, AU, ⁷University of California San Francisco Comprehensive Cancer Center, San Francisco, US, ⁸University Hospital Heidelberg, Heidelberg, DE, ⁹Dana-Farber Cancer Institute, Boston, US, ¹⁰Genentech, Inc., South San Francisco, US, ¹¹F. Hoffmann-La Roche, Ltd., Basel, CH, ¹²Genentech, Inc. - Member of the Roche Group, South San Francisco, US, ¹³Barts Cancer Institute-Queen Mary University of London, London, GB

19:35 - 19:40 **5MO - Evaluation of pathological complete response (pCR) after neoadjuvant chemo-radiation therapy for primary breast cancer (JCOG0306A1)**

T. Shien¹, H. Tsuda², K. Sasaki³, J. Mizusawa³, F. Akiyama⁴, M. Kurosumi⁵, M. Sawaki⁶, N. Tamura⁷, K. Tanaka⁷, M. Takahashi⁸, N. Hayashi⁹, H. Mukai¹⁰, N. Masuda¹¹, H. Iwata¹², ¹Okayama University Hospital, Okayama, JP, ²National Defense Medical College, Saitama, JP, ³JCOG, Tokyo, JP, ⁴Cancer Institute Hospital, Tokyo, JP, ⁵Kameda Kyobashi Clinic, Tokyo, JP, ⁶Aichi Cancer Center Hospital, Aichi, JP, ⁷Toranomon Hospital, Tokyo, JP, ⁸National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ⁹St` Lukes International Hospital, Tokyo, JP, ¹⁰National Cancer Center Hospital East, Tokyo, JP, ¹¹National Hospital Organization Osaka National Hospital, Osaka, JP, ¹²Aichi Cancer Center Hospital, Nagoya, JP

19:40 - 19:48 **Invited Discussant abstracts 3MO, 49MO and 5MO**

J.W.-H. Tsang, HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK

19:48 - 19:56 **LIVE Q&A**



- 19:56 - 20:01 **4MO - Machine learning intratumoral and peritumoral magnetic resonance imaging radiomics for predicting disease-free survival in patients with early-stage breast cancer (RBC-01 Study)**
W. Ren¹, Y. Yu¹, Y. Tan¹, Y. Chen², J. Liu¹, Z. He¹, A. Li³, J. Ma¹, N. Lu⁴, C. Li¹, X. Li⁵, Q. Ou¹, K. Chen¹, Q. Hu⁵, J. Ouyang⁶, F. Su¹, C. Xie⁴, E. Song¹, H. Yao¹, ¹2nd Affiliated Hospital/Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, CN, ²The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ³Guangdong Medical University, Zhanjiang, CN, ⁴Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁵Shunde Hospital, Southern Medical University, Foshan, CN, ⁶Tungwah Hospital, Sun Yat-sen University, Dongguan, CN
- 20:01 - 20:07 **Invited Discussant abstract 4MO**
P. Lambin, Maastricht University, Maastricht, NL
- 20:07 - 20:15 **LIVE Q&A**
- 18:45 - 20:05 Type: Mini Oral session Channel 3**
Title: Mini oral session on Thoracic cancers
 Chair: Takashi Seto, JP
- 18:45 - 18:50 **378MO - EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >50%**
A. Sezer¹, S. Kilickap², M. Gümüş³, I. Bondarenko⁴, M. Özgüroğlu⁵, M. Gogishvili⁶, H.M. Turk⁷, İ. Çiçin⁸, D. Bentsion⁹, O. Gladkov¹⁰, P. Clingan¹¹, V. Sriuranpong¹², N. Rizvi¹³, S. Li¹⁴, S. Lee¹⁴, G. Gullo¹⁵, I. Lowy¹⁵, P. Rietschel¹⁵, ¹Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., Adana, TR, ²Hacettepe University Cancer Institute, Ankara, TR, ³School of Medicine, Istanbul Medeniyet University, Istanbul, TR, ⁴Dnipropetrovsk city multidisciplinary clinical hospital №4, Dnipro, UA, ⁵Division of Medical Oncology Clinical Trial Unit, Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, TR, ⁶University Clinic Ltd, Tbilisi, GE, ⁷Bezmialem Vakif University, Medical Faculty, Istanbul, TR, ⁸Trakya University Faculty of Medicine, Edirne, TR, ⁹Sverdlovsk Regional Oncology Centre, Sverdlovsk, RU, ¹⁰“EVIMED”, Chelyabinsk, RU, ¹¹University of Wollongong/Illawarra Cancer Centre, Wollongong Hospital, Wollongong, AU, ¹²Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, TH, ¹³Columbia University Medical Center, New York, US, ¹⁴Regeneron Pharmaceuticals, Inc., Basking Ridge, US, ¹⁵Regeneron Pharmaceuticals, Inc., Tarrytown, US
- 18:50 - 18:55 **379MO - Durvalumab (D) + tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN**
J.H. Ji¹, J. Goldman², M. Garassino³, Y. Chen⁴, N. Reinmuth⁵, K. Hotta⁶, A. Poltoratskiy⁷, D. Trukhin⁸, M. Hochmair⁹, M. Özgüroğlu¹⁰, G. Statsenko¹¹, O. Voitko¹², N. Conev¹³, I. Bondarenko¹⁴, S. Spencer¹⁵, M. Xie¹⁶, S. Jones¹⁵, A. Franks¹⁷, Y. Shrestha¹⁷, L. Paz-Ares¹⁸, ¹Samsung Changwon Hospital Sung Kyun Kwan University, Changwon, KR, ²David Geffen School of Medicine at UCLA, Los Angeles, US, ³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁴Cancer & Hematology Centers of



Western Michigan, Grand Rapids, US, ⁵Asklepios Lung Clinic, Munich-Gauting, DE, ⁶Okayama University Hospital, Okayama, JP, ⁷Petrov Research Institute of Oncology, St. Petersburg, RU, ⁸Odessa Regional Cancer Center, Odessa, UA, ⁹Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, ¹⁰Division of Medical Oncology Clinical Trial Unit, Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, TR, ¹¹OMSK Regional Oncology Center, Omsk, RU, ¹²Kyiv City Clinical Oncological Centre, Kiev, UA, ¹³Clinic of Medical Oncology, UMHAT St Marina, Varna, BG, ¹⁴Dnipropetrovsk city multidisciplinary clinical hospital №4, Dnipro, UA, ¹⁵AstraZeneca, Cambridge, GB, ¹⁶AstraZeneca, Boston, US, ¹⁷AstraZeneca USA, Gaithersburg, US, ¹⁸University Hospital 12 De Octubre and Universidad Complutense & CiberOnc, Madrid, ES

18:55 - 19:00 **380MO - A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure**

T.C. Lam¹, K. Tsang¹, H. Choi¹, V.H.F. Lee², K.O. Lam³, C.L. Chiang¹, T.H. So⁴, W.W. Chan³, S.F. Nyaw⁵, F. Lim⁶, J.O. Lau⁷, J. Chik⁸, S.F. Kong³, A.W.M. Lee³, ¹The University of Hong Kong, Hong Kong, HK, ²University of Hong Kong, Hong Kong, HK, ³The University of Hong Kong Li Ka Shing Faculty of Medicine, Pokfulam, HK, ⁴Queen Mary Hospital, Hong Kong, HK, ⁵Tuen Mun Hospital, Hong Kong, HK, ⁶Princess Margaret Hospital, Hong Kong, HK, ⁷Pamela Youde Nethersole Eastern Hospital, Hong Kong, HK, ⁸Queen Elizabeth Hospital, Hong Kong, HK

19:00 - 19:08 **Invited Discussant abstracts 378MO, 379MO and 380MO**

Y.-L. Wu, Guangdong Lung Cancer Institute, Guangzhou, CN

19:08 - 19:16 **LIVE Q&A**

19:16 - 19:21 **356MO - Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence**

M. Tsuboi¹, Y.-L. Wu², J. He³, T. John⁴, C. Grohe⁵, M. Majem⁶, J. Goldman⁷, K. Laktionov⁸, S.-W. Kim⁹, T. Kato¹⁰, H.V. Vu¹¹, C. Akewanlop¹², C.-J. Yu¹³, F. De Marinis¹⁴, M. Domine¹⁵, F. Shepherd¹⁶, C. Yan¹⁷, A. Atasoy¹⁷, R. Herbst¹⁸, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Guangdong Lung Cancer Institute, Guangzhou, CN, ³National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁴Austin Health, Melbourne, AU, ⁵Evangelische Lungenklinik, Berlin, DE, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁷David Geffen School of Medicine at UCLA, Los Angeles, US, ⁸FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁹Asan Medical Center, University of Ulsan College of Medicine, Seoul, CN, ¹⁰Kanagawa Cancer Center, Yokohama, JP, ¹¹Choray Hospital, Ho Chi Minh City, VN, ¹²Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH, ¹³National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TW, ¹⁴European Institute of Oncology (IEO), IRCCS, Milan, IL, ¹⁵Instituto de Investigacion Sanitaria-Fundación Jimenez Diaz (IIS- FJD), Madrid, ES, ¹⁶University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto, CA, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸Yale School of Medicine and Yale Cancer Center, New Haven, US



- 19:21 - 19:26 **366MO - Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study**
- S.-W. Kim¹, D. Planchard², P.-H. Feng³, N. Karaseva⁴, T.M. Kim⁵, C.K. Lee⁶, A. Poltoratskiy⁷, N. Yanagitani⁸, S. Powar⁹, X. Huang⁹, P. Howarth⁹, P. Jänne¹⁰, K. Kobayashi¹¹, ¹Asan Medical Center, Seoul, KR, ²Institut Gustave Roussy, Villejuif, FR, ³Taipei Medical University, Taipei, TW, ⁴City Oncological Hospital, St. Petersburg, RU, ⁵Seoul National University Hospital, Seoul, KR, ⁶St. George Hospital, Kogarah, Sydney, AU, ⁷Petrov Research Institute of Oncology, St. Petersburg, RU, ⁸The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, ⁹AstraZeneca, Cambridge, GB, ¹⁰Dana-Farber Cancer Institute, Boston, US, ¹¹Saitama Medical University, Moroyama, JP
- 19:26 - 19:31 **381MO - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)**
- D. Hong¹, Y.-J. Bang², F. Barlesi³, G. Durm⁴, G. Falchook⁵, R. Govindan⁶, G. Dy⁷, K. Park⁸, J. Strickler⁹, T. Burns¹⁰, J. Kim¹¹, A. Ang¹², J.R. Lipford¹¹, G. Ngarmchamnanrith¹¹, A. Anderson¹¹, B. Li¹³, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Seoul National University Hospital, Seoul, KR, ³Aix Marseille University, Marseille, FR, ⁴Division of Hematology/Oncology, Indianapolis, US, ⁵Sarah Cannon Research Institute, New York, US, ⁶Washington University School of Medicine, St. Louis, US, ⁷Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁸Sungkyunkwan University School of Medicine, Seoul, KR, ⁹Duke Cancer Center, Durham, US, ¹⁰University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, US, ¹¹Amgen Inc., Thousand Oaks, US, ¹²Amgen, Inc., Thousand Oaks, US, ¹³Memorial Sloan Kettering Cancer Center, New York, US
- 19:31 - 19:36 **382MO - The preliminary safety result of a phase II study of osimertinib in combination with platinum + pemetrexed in patients with previously untreated EGFR-mutated advanced NSCLC (NEJ032C/LOGIK1801: OPAL)**
- R. Morita¹, H. Asahina², K. Tanaka³, R. Saito⁴, S. Sugawara⁵, R. Ko⁶, K. Azuma⁷, S. Morita⁸, Y. Saijo⁹, M. Maemondo¹⁰, M. Seike¹¹, O. Isamu³, K. Sugio¹², K. Kobayashi¹³, ¹Akita Kousei Medical Center, Akita, JP, ²Hokkaido University Hospital, Sapporo, JP, ³Kyushu University, Fukuoka, JP, ⁴Tohoku University, Sendai, JP, ⁵Sendai Kousei Hospital, Sendai, JP, ⁶Juntendo University Graduate School of Medicine, Tokyo, JP, ⁷Kurume University School of Medicine, Kurume, JP, ⁸Kyoto University Graduate School of Medicine, Kyoto, JP, ⁹Niigata University Graduate School of Medical and Dental Sciences, Niigata University, Niigata, JP, ¹⁰Iwate Medical University School of Medicine, Morioka, JP, ¹¹Nippon Medical School, Tokyo, JP, ¹²Oita University Faculty of Medicine, Oita, JP, ¹³Saitama Medical University International Medical Center, Hidaka, JP
- 19:36 - 19:41 **383MO - Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping**
- J.C.-H. Yang¹, X. Le², B. Cho³, J.-Y. Han⁴, M. Morise⁴, Y.-M. Chen⁵, J.-H. Kang⁶, T. Kato⁷, H. Takeoka⁸, K. Chikamori⁹, H. Sakai¹⁰, K. Park¹¹, Y.-L. Wu¹², K. Schumacher¹³, R. Bruns¹³, J. Straub¹³, P. Paik¹⁴, ¹National Taiwan University Hospital, Taipei, TW, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Yonsei University



College of Medicine, Seoul, KR, ⁴Nagoya University Graduate School of Medicine, Nagoya, JP, ⁵Taipei Veterans General Hospital, Taipei, TW, ⁶Seoul St. Mary's Hospital, Seoul, KR, ⁷Kanagawa Cancer Center, Yokohama, JP, ⁸NHO Kyushu Medical Center, Fukuoka-shi, JP, ⁹NHO Yamaguchi - Ube Medical Center, Ube-shi, JP, ¹⁰Saitama Cancer Center, Saitama, JP, ¹¹Sungkyunkwan University School of Medicine, Seoul, KR, ¹²Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ¹³Merck KGaA, Darmstadt, DE, ¹⁴Memorial Sloan Kettering Cancer Center, New York, US

19:41 - 19:53 **Invited Discussant abstracts 356MO, 366MO, 381MO, 382MO and 383MO**
R.A. Soo, National University Hospital, Singapore, SG

19:53 - 20:03 **LIVE Q&A**

18:45 - 20:20 Type: Mini Oral session Channel 4
Title: Mini oral session on Developmental and precision medicine
 Chair: Joaquin Mateo, ES

18:45 - 18:50 **LBA3 - Early detection and localization of multiple cancers using a blood-based methylation assay (ELSA-seq)**
Q. Gao¹, B. Li², S. Cai², J. Xu², C. Wang², S. Fang², F. Qiu², J. Su², F. Xu², X. Wen², Y. Zhang², G. Wang², H. Liu², Z. Zhang³, ¹Zhongshan Hospital, Fudan University, Shanghai, CN, ²Burning Rock Biotech, Shanghai, CN, ³Burning Rock Dx, Shanghai, CN

18:50 - 18:55 **299MO - Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC**
D.S.W. Tan¹, M.-J. Ahn², C.-H. Chiu³, Y. Ohe⁴, H.H.F. Loong⁵, C.E. Chee⁶, S.-W. Kim⁷, M. Takeda⁸, Y.-C. Li⁹, A. Cheng¹⁰, T. Hida¹¹, D.-W. Kim¹², N. Nogami¹³, W.-C. Su¹⁴, H. Tanaka¹⁵, S. Osborne¹⁶, R. Freund¹⁶, D. Chen¹⁷, T. Seto¹⁸, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ³Taipei Veterans General Hospital, Taipei City, TW, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, HK, ⁶National University Hospital, Singapore, SG, ⁷Asan Medical Centre, Seoul, KR, ⁸Kindai University Hospital, Osakasayama, JP, ⁹Hong Kong United Oncology Centre, Kowloon, HK, ¹⁰Princess Margaret Hospital, Kwai Chung, HK, ¹¹Aichi Cancer Center Hospital, Nagoya, JP, ¹²Seoul National University Hospital, Seoul, KR, ¹³NHO Shikoku Cancer Center, Matsuyama, JP, ¹⁴National Cheng Kung University Hospital, Tainan, TW, ¹⁵Niigata Cancer Center Hospital, Niigata, JP, ¹⁶F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁷Genentech Inc., South San Francisco, US, ¹⁸National Hospital Organization Kyushu Cancer Center, Fukuoka, JP

18:55 - 19:00 **300MO - Impact of dihydropyrimidine dehydrogenase (DPD) genotype on fluoropyrimidine-related toxicity in Asian population**
M. Kanai¹, T. Kawaguchi², M. Kotaka³, D. Manaka⁴, J. Hasegawa⁵, A. Takagane⁶, Y. Munemoto⁷, T. Kato⁸, T. Eto⁹, T. Touyama¹⁰, T. Matsui¹¹, K. Shinozaki¹², T. Mizushima¹³, S. Matsumoto², M. Mori¹⁴, A. Ohtsu¹⁵, S. Saji¹⁶, T. Yoshino¹⁵, F. Matsuda², ¹Kyoto



University Hospital, Kyoto, JP, ²Kyoto University Graduate School of Medicine, Kyoto, JP, ³Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, ⁴Kyoto Katsura Hospital, Kyoto, JP, ⁵Osaka Rosai Hospital, Sakai, JP, ⁶Hakodate Goryoukaku Hospital, Hakodate, JP, ⁷Fukui Prefecture Saiseikai Hospital, Fukui, JP, ⁸National Hospital Organization Osaka National Hospital, Osaka, JP, ⁹Tsuchiura Kyodo General Hospital, Ibaraki, JP, ¹⁰Nakagami Hospital, Okinawa, JP, ¹¹Matsui-nyg@umin.ac.jp Aichi cancer center Aichi hospital, Okazaki, JP, ¹²Hiroshima Prefectural Hospital, Hiroshima, JP, ¹³Osaka University Graduate School of Medicine, Suita, JP, ¹⁴Kyushu University, Fukuoka, JP, ¹⁵National Cancer Center Hospital East, Kashiwa, JP, ¹⁶Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, JP

- 19:00 - 19:08 **Invited Discussant abstracts LBA3, 299MO and 300MO**
C.-C. Lin, National Taiwan University Hospital, Taipei city, TW
- 19:08 - 19:16 **LIVE Q&A**
- 19:16 - 19:21 **301MO - Genomic HLA as a predictive biomarker for survival among non-small cell lung cancer patient treated with single agent immunotherapy**
A. Abed¹, L. Calapre², J. Lo², S. Correia¹, S. Bowyer³, A. Chopra⁴, M. Watson⁴, M. Khattak⁵, M. Millward⁶, E. Gray², ¹Fiona Stanley Hospital, Perth, AU, ²Edith Cowan University, Joondalup, AU, ³Sir Charles Gairdner Hospital, NEDLANDS, AU, ⁴Health Futures Institute, Murdoch, AU, ⁵Fiona Stanley Hospital, Murdoch, AU, ⁶School of Medicine and Pharmacology Sir Charles Gairdner Hospital, Nedlands, AU
- 19:21 - 19:26 **302MO - Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors**
J.-G. Zhou¹, A. Donaubaue², B. Frey², I. Becker², S. Rutzner², M. Eckstein², R. Sun³, H. Ma⁴, P. Schubert², C. Schweizer², R. Fietkau², E. Deutsch³, U. Gaip², M. Hecht², ¹Zunyi Medical College Affiliated Hospital, Zunyi, CN, ²Universitätsklinikum Erlangen, Erlangen, DE, ³Institut Gustave Roussy, Villejuif Cedex, FR, ⁴Zunyi Medical College Affiliated Hospital, Zunyi City, CN
- 19:26 - 19:31 **303MO - Single-cell analysis reveals the interaction between M2 macrophages and NK cells underlying immune types associated with cancer immunotherapy response**
A. Li¹, W. Zhang¹, Y. Yu², Y. Chen³, Q. Ou², X. Tang¹, H. Yao², ¹Guangdong Medical University, Zhanjiang, CN, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, ³The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN
- 19:31 - 19:39 **Invited Discussant abstracts 301MO, 302MO and 303MO**
I. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
- 19:39 - 19:47 **LIVE Q&A**



- 19:47 - 19:52 **70MO - Efficacy and safety of envafolimab (KN035) in advanced tumours with mismatch-repair deficiency**
 L. Shen¹, J. Li¹, Y. Deng², W. Zhang³, A. Zhou⁴, W. Guo⁵, J. Yang⁶, Y. Yuan⁷, L. Zhu⁸, S. Qin⁹, S. Xiang¹⁰, L. Li¹¹, H. Lu¹², J. Gong¹³, T. Xu¹⁴, D. Liu¹³, ¹Beijing Cancer Hospital, Beijing, CN, ²The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ³The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁴Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ⁵Fudan University Shanghai Cancer Center, Shanghai, CN, ⁶Fujian Provincial Cancer Hospital, Fuzhou, CN, ⁷The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ⁸Jiangsu Cancer Hospital, Nanjing, Nanjing, CN, ⁹The 81 Hospital of the Chinese People's Liberation Army, Nanjing, CN, ¹⁰3DMedicine, Beijing, CN, ¹¹3DMedicine, Beijing, CN, ¹²3DMedicine Co. Ltd., Sichuan, CN, ¹³3DMedicine Co. Ltd., Sichuan, CN, ¹⁴Alphamab Co. Ltd., Suzhou, CN
- 19:52 - 19:57 **71MO - OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial**
 H.-S. Shiah¹, J.F. Strauss², C.-C. Lin³, C.-C. Ou⁴, Y. Yen⁵, ¹Taipei Medical University, Taipei City, TW, ²Mary Crowley Cancer Research Center, Dallas, US, ³National Taiwan University Hospital, Taipei City, TW, ⁴OBI Pharma, Taipei City, TW, ⁵Taipei Medical University, Taipei City, TW
- 19:57 - 20:02 **72MO - Selinexor in combination with standard chemotherapy in patients with advanced solid tumours: Results of an open label, single-center, multi-arm phase Ib study**
 K. Thein¹, A.M. Tsimberidou¹, S. Piha-Paul², F. Janku³, D. Karp⁴, S. Fu¹, A. Zarifa², J. Gong², D. Hong³, T. Yap³, V. Subbiah³, S. Pant⁵, F. Meric-Bernstam³, A. Naing³, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, US, ³The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁴UT MD Anderson Cancer Center, Houston, US, ⁵MD Anderson Cancer Center, Houston, US
- 20:02 - 20:10 **Invited Discussant abstracts 70MO, 71MO and 72MO**
 J. Lopez, The Royal Marsden Hospital NHS Foundation Trust, Sutton, GB
- 20:10 - 20:18 **LIVE Q&A**
- 18:45 - 20:00 Type: Young Oncologist session Channel 5**
Title: Clinical cases discussion 1
 Chair: Kevin Punie, BE; Kok Haw Jonathan Lim, GB
- 18:45 - 18:50 **YO1 - Early Stage Breast Cancer- A Case Report**
 U. Jithin, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, CN
- 18:50 - 18:55 **YO3 - Breast Cancer Presenting as Superior Vena Cava Syndrome: the Crucial Role of Emergent Chemotherapy**
 R. Velasco, H.N. Tan, M. Basamayor, J. Ignacio, University of the Philippines - Philippine



General Hospital, Manila, PH

- 18:55 - 19:00 **YO4 - Losing One's Voice: Vocal Cord Paralysis and Receptor Conversion in Metastatic Breast Cancer**
H.N. Tan, L.I. Catedral, R. Velasco, M. San Juan, University of the Philippines - Philippine General Hospital, Manila, PH
- 19:00 - 19:10 **Live Q&A and live discussion**
K. Punie, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 19:10 - 19:15 **YO14 - Exceptional Response to Pembrolizumab in Metastatic Prostate Cancer with High Tumour Mutation Burden and Multiple Somatic Mutations**
T.H. So¹, D.Y.L. Chow¹, T.C. Lam², V.H.F. Lee², ¹Queen Mary Hospital, Hong Kong, HK, ²University of Hong Kong, Hong Kong, HK
- 19:15 - 19:20 **YO17 - Acute interstitial nephritis (AIN) in a patient with Tumour mutation burden (TMB)-high Cancer of Unknown Primary (CUP) on combination immune checkpoint blockade (ICB)**
J. Lee¹, H.Z. Tan², A. Loh², D.S.W. Tan¹, J. Choo², ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Singapore General Hospital, Singapore, SG
- 19:20 - 19:25 **YO20 - Primary Pulmonary Lymphoepithelioma-like Carcinoma Responded to Both Anti-PD1 and Anti-PD-L1 Inhibitors: A Case Report**
A. Archwamety¹, C. Akewanlop², R. Ruangchira-Urai², K. Korphaisarn², ¹Mahidol University - Faculty of Medicine - Siriraj Hospital, Bangkok, TH, ²Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH
- 19:25 - 19:30 **YO21 - EGFR mutated lung adenocarcinoma (LUAC) with Osimertinib refractory squamous cell transformation presenting prolonged response to anti-PD-1 immunotherapy**
L.B. Mendes Gomes, C. De Liz, H. Carioca Freitas, D. Carraro, G. Tardin Torrezan, A.C. Camargo Cancer Center - Fundacao Antonio Prudente, Sao Paulo, BR
- 19:30 - 19:35 **YO23 - Immune Checkpoint Inhibitors to Metastatic Melanoma and Renal Allograft Rejection: A case report**
D. Santana, M. Tavares, A.C. Camargo Cancer Center - Fundacao Antonio Prudente, Sao Paulo, BR
- 19:35 - 19:55 **Live Q&A and live discussion**
K.H.J. Lim, The Christie NHS Foundation Trust, Manchester, GB



20:30 - 22:00 **Type: Special Session** **Channel 1**
Title: Joint SITC-ESMO Immunotherapy Primer 1
Chair: Daniel Weng Tan,

20:30 - 20:50 **Immune checkpoint inhibitors, humble beginnings and back to the future**
H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

20:50 - 21:10 **Biomarker-driven approaches to guide clinical care**
E. Romano, Institut Curie, Paris, FR

21:10 - 21:30 **Combination approaches to immune checkpoint inhibitors**
D.S.W. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

21:30 - 22:00 **Live Q&A and live discussion**



21-11-2020

12:00 - 13:30	Type: Industry Satellite Symposium Title: AstraZeneca - Improving patient outcomes in early-stage and advanced EGFR-mutant NSCLC: Emerging strategies Chair: Chee Khoon Lee, AU	Channel 1
----------------------	---	------------------

12:00 - 13:15 **Improving patient outcomes in early-stage and advanced EGFR-mutant NSCLC: Emerging strategies**

C.K. Lee¹, O. Boon Hean², S.-W. Wong³, ¹St. George Hospital, Kogarah, Sydney, AU, ²Duke-NUS Graduate Medical School, Singapore, SG, ³The Cancer Centre at Paragon, Singapore, SG

13:15 - 13:30 **Live audience Q&A**

C.K. Lee¹, O. Boon Hean², S.-W. Wong³, R. Sanborn⁴, W. Cooper⁵, ¹St. George Hospital, Kogarah, Sydney, AU, ²Duke-NUS Graduate Medical School, Singapore, SG, ³The Cancer Centre at Paragon, Singapore, SG, ⁴Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, ⁵The University of Sydney School of Public Health, Sydney, AU



12:00 - 13:30	Type: Industry Satellite Symposium Title: AstraZeneca - Emerging immuno-oncology combinations for the treatment of HCC Chair: Stephen Chan, HK	Channel 2
12:00 - 12:05	Welcome and introduction <u>S. Chan</u> , The Chinese University of Hong Kong, Hong Kong, HK	
12:05 - 12:25	Immune checkpoint molecules: key players in the pathogenesis of HCC <u>I. Melero</u> , Clinica Universitaria de Navarra, Pamplona, ES	
12:25 - 12:40	Optimising the immune response: exploring high-dose priming with anti-CTLA-4 therapy in unresectable HCC <u>S. Chan</u> , The Chinese University of Hong Kong, Hong Kong, HK	
12:40 - 12:55	Recent advances in the treatment of unresectable HCC <u>G. Abou-Alfa</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
12:55 - 13:15	Clinical experience in unresectable HCC <u>S.P. Choo</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
13:15 - 13:30	Live Q&A <u>S. Chan</u> ¹ , <u>G. Abou-Alfa</u> ² , <u>S.P. Choo</u> ³ , <u>I. Melero</u> ⁴ , ¹ The Chinese University of Hong Kong, Hong Kong, HK, ² Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ³ NCCS - National Cancer Centre Singapore, Singapore, SG, ⁴ Clinica Universitaria de Navarra, Pamplona, ES	



12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 3**
Title: Pfizer - Beyond 2020: Targeting EGFR Exon 19 and Exon 21 L858R in the New Era
 Chair: Ross Soo, SG

12:00 - 12:10 **Opening remarks and introduction**
R.A. Soo, National University Hospital, Singapore, SG

12:10 - 12:35 **Dissecting the molecular differences and clinical outcomes of EGFR patients with Exon 19 deletion and Exon 21 L858R mutations**
Y.-L. Wu, Guangdong Lung Cancer Institute, Guangzhou, CN

12:35 - 12:50 **Case based discussion**
U. Batra, Rajiv Gandhi Cancer Institute & Research Center, New Delhi, IN

12:50 - 13:20 **Panel discussion and closing**
R.A. Soo¹, Y.-L. Wu², U. Batra³, N. Cheah Lay Chin⁴, ¹National University Hospital, Singapore, SG, ²Guangdong Lung Cancer Institute, Guangzhou, CN, ³Rajiv Gandhi Cancer Institute & Research Center, New Delhi, IN, ⁴Loh Guan Lye Specialist Centre, George Town, MY

12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 4**
Title: Medscape Oncology Global - Stepping it up with Comprehensive Genomic Profiling (CGP): How can we harness the opportunities?
 Chair: James Chih-Hsin Yang, TW

12:00 - 13:10 **Stepping it up with Comprehensive Genomic Profiling (CGP): How can we harness the opportunities?**
J.C.-H. Yang¹, D.S. Tan², L. Mileskin³, S. Fox⁴, ¹NTUH - National Taiwan University Hospital, Taipei City, TW, ²NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ³Peter MacCallum Cancer Center, Melbourne, AU, ⁴Peter MacCallum Cancer Centre, Melbourne, AU

13:10 - 13:30 **(Live) Stepping it up with CGP: Tackling the key questions and challenges**
J.C.-H. Yang¹, D.S. Tan², L. Mileskin³, S. Fox⁴, ¹NTUH - National Taiwan University Hospital, Taipei City, TW, ²NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ³Peter MacCallum Cancer Center, Melbourne, AU, ⁴Peter MacCallum Cancer Centre, Melbourne, AU



12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 5**
Title: MSD - Advances in RCC & TNBC: A Focus on Immuno-Oncology (IO)
 Chair: Rebecca Dent, SG

12:00 - 13:15 **Advances in RCC & TNBC: A Focus on Immuno-Oncology (IO)**
R. Dent¹, Y.H. Park², J.W.-C. Chang³, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ³Chang Gung Medical Foundation- Taipei Chang Gung Memorial Hospital, Taipei City, TW

13:15 - 13:30 **Q&A and Closing**
R. Dent¹, Y.H. Park², J.W.-C. Chang³, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ³Chang Gung Medical Foundation-Linkou, Taoyuan, TW

12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 6**
Title: MSD - Advances in Gastrointestinal Cancers: A Focus on Immuno-Oncology (IO)
 Chair: Han Chong Toh, SG

12:00 - 13:10 **Advances in Gastrointestinal Cancers: A Focus on Immuno-Oncology (IO)**
H.C. Toh¹, H.L. Kong², A. Zhu³, Y. Janjigian⁴, K. Kato⁵, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Icon SOC - Mount Elizabeth, Singapore, SG, ³Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP

13:10 - 13:30 **Interactive Q&A**
H.C. Toh¹, H.L. Kong², A. Zhu³, Y. Janjigian⁴, K. Kato⁵, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Icon SOC - Mount Elizabeth, Singapore, SG, ³Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP



12:00 - 13:30 **Type: Industry Satellite Symposium** **Channel 7**
Title: Physicians' Education Resource - Leveraging Novel Antibody-Drug Conjugates in a World of Evolving Treatment Paradigms: A Pan-Tumour Perspective
 Chair: Masakazu Toi, JP

12:00 - 13:20 **Leveraging Novel Antibody-Drug Conjugates in a World of Evolving Treatment Paradigms: A Pan-Tumour Perspective**
M. Toi¹, J. Tabernero², M. Péro³, ¹Kyoto University-Graduate school of medicine, Kyoto, JP, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Centre Léon Bérard, Lyon, FR

13:20 - 13:30 **Post session Survey and Q&A Session**
M. Toi, Kyoto University-Graduate school of medicine, Kyoto, JP

14:00 - 15:45 **Type: Proffered Paper session** **Channel 1**
Title: Proffered paper session on Breast cancer
 Chair: Sung-Bae Kim, KR

14:00 - 14:12 **10 - KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)**
R. Dent¹, J. Cortes², L. Pusztai³, H.L. McArthur⁴, S. Kuemmel⁵, J. Bergh⁶, C. Denkert⁷, Y.H. Park⁸, R. Hui⁹, N. Harbeck¹⁰, M. Takahashi¹¹, T. Foukakis⁶, P.A. Fasching¹², F. Cardoso¹³, L. Jia¹⁴, E. Jensen¹⁴, V. Karantza¹⁵, G. Aktan¹⁵, J. O'Shaughnessy¹⁶, P. Schmid¹⁷, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²IOB Institute of Oncology, Barcelona, ES, ³Yale University School of Medicine, New Haven, US, ⁴Cedars-Sinai Medical Center, Los Angeles, US, ⁵Kliniken Essen-Mitte Evang, Huysens-Stiftung, Essen, DE, ⁶Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Solna, SE, ⁷Philipps University Marburg, Marburg, DE, ⁸Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ⁹Westmead Hospital and the University of Sydney, Sydney, AU, ¹⁰LMU University Hospital, Munich, DE, ¹¹NKO Hokkaido Cancer Center, Sapporo, JP, ¹²Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, DE, ¹³Champalimaud Foundation Cancer Center, Lisbon, PT, ¹⁴Merck & Co., Inc., Kenilworth, US, ¹⁵Merck & Co, Kenilworth, US, ¹⁶Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ¹⁷Barts Cancer Institute-Queen Mary University of London, London, GB

14:12 - 14:24 **430 - Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia**
M. Md Yusof¹, D.W. Cescon², H.S. Rugo³, S.-A. Im⁴, C. Gallardo⁵, O. Lipatov⁶, C.H. Barrios⁷, E. Holgado⁸, H. Iwata⁹, N. Masuda¹⁰, E. Gokmen¹¹, S. Loi¹², Z. Guo¹³, E. Jensen¹³, G. Aktan¹³, V. Karantza¹³, P. Schmid¹⁴, J. Cortes¹⁵, ¹Pantai Medical Centre, Kuala Lumpur, MY, ²Princess Margaret Cancer Centre, Toronto, CA, ³University of California San Francisco Comprehensive Cancer Center, San Francisco, US, ⁴Seoul National University Hospital, Seoul, KR, ⁵Arturo Lopez Perez Foundation, Santiago, CL,



⁶Republican Clinical Oncology Dispensary, Republic of Bashkortostan, RU, ⁷Centro de Pesquisa em Oncologia, HSL, PUCRS, Porto Alegre, BR, ⁸and Breast Cancer Program, IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, ES, ⁹Aichi Cancer Center Hospital, Nagoya, JP, ¹⁰National Hospital Organization, Osaka National Hospital, Osaka, JP, ¹¹Ege University Medical Faculty, Izmir, TR, ¹²Peter MacCallum Cancer Institute, Melbourne, AU, ¹³Merck & Co., Inc., Kenilworth, US, ¹⁴Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, GB, ¹⁵and Breast Cancer Research Program, Vall d'Hebron Institute of Oncology (VHIO), Madrid & Barcelona, ES

14:24 - 14:36

440 - Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation

S.-A. Im¹, J. Cortes², O. Lipatov³, A. Goncalves⁴, K.-S. Lee⁵, P. Schmid⁶, K. Tamura⁷, L. Testa⁸, I. Witzel⁹, S. Ohtani¹⁰, S. Zambelli¹¹, N. Harbeck¹², F. Andre¹³, R. Dent¹⁴, J. Lin¹⁵, V. Karantza¹⁶, J.A. Mejia¹⁶, E. Winer¹⁷, ¹SNUH-Seoul National University Hospital, Seoul, KR, ²Vall d'Hebron Institute of Oncology, Barcelona, ES, ³Republican Clinical Oncology Dispensary, Republic of Bashkortostan, RU, ⁴Institute Paoli Calmettes, Marseille, FR, ⁵National Cancer Center, Gyeonggi-do, KR, ⁶Barts Cancer Institute-Queen Mary University of London, London, GB, ⁷National Cancer Center Hospital, Tokyo, JP, ⁸Oncocenter Serviços Médicos LTDA, Sao Paulo, BR, ⁹UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ¹⁰Hiroshima City Hospital, Hiroshima, JP, ¹¹San Raffaele Scientific Institute, Milan, IT, ¹²LMU University Hospital, Munich, DE, ¹³Faculté de Médecine Paris-Sud XI, Gustave Roussy, Villejuif, FR, ¹⁴NCCS - National Cancer Centre Singapore, Singapore, SG, ¹⁵Merck & Co., Inc., Kenilworth, US, ¹⁶Merck & Co, Kenilworth, US, ¹⁷Harvard Medical School, Boston, US

14:36 - 14:48

Invited Discussant abstracts 10, 430 and 440

E. De Azambuja, Institute Jules Bordet, Brussels, BE

14:48 - 14:58

LIVE Q&A

14:58 - 15:10

450 - Abemaciclib plus fulvestrant in East Asian women with HR⁺, HER2-advanced breast cancer: Overall survival from MONARCH 2

C.-S. Huang¹, M. Toi², Y.-H. Im³, H. Iwata⁴, J. Sohn⁵, H.-C. Wang⁶, N. Masuda⁷, S.-A. Im⁸, Y. Lu⁹, N. Haddad⁹, S. Sakaguchi⁹, K. Hurt⁹, P. Neven¹⁰, A. Llombart-Cussac¹¹, G. Sledge¹², ¹National Taiwan University Hospital, Taipei, TW, ²Kyoto University Hospital, Kyoto, JP, ³Samsung Medical Center, Seoul, KR, ⁴Aichi Cancer Center Hospital, Nagoya, JP, ⁵Yonsei University Health System, Seoul, KR, ⁶a, a, TW, ⁷National Hospital Organization Osaka National Hospital, Osaka, JP, ⁸SNUH-Seoul National University Hospital, Seoul, KR, ⁹Eli Lilly and Company, Indianapolis, US, ¹⁰University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹¹Hospital Universitario Arnau de Vilanova, Lleida, ES, ¹²Stanford University, Stanford, US

15:10 - 15:22

460 - Neratinib & capecitabine (N&C) vs lapatinib & capecitabine (L&C) in Asians with HER2⁺ metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial



M.S. Dai¹, Y.H. Feng², S.W. Chen³, N. Masuda⁴, T. Sangai⁵, T. Yau⁶, A. Kwong⁶, R. Ngan⁶, Y.S. Yap⁷, P.C.S. Ang⁸, S. Ow⁹, K.S. Lee¹⁰, S.B. Kim¹¹, H.C. Chung¹², K. Keyvanjah¹³, J. Bebchuk¹³, M.-C. Chen¹⁴, ¹Tri-Service General Hospital - Neihu Branch, Taipei City, TW, ²Chi Mei Medical Center-YK Branch, Tainan, TW, ³Chi Mei Medical Center-LiouYing Branch, Tainan, TW, ⁴National Hospital Organization Osaka National Hospital, Osaka, JP, ⁵Kitasato University School of Medicine, Sagamihara, Kanagawa, JP, ⁶The University of Hong Kong - Queen Mary Hospital, Hong Kong, HK, ⁷National Cancer Centre Singapore, Singapore, SG, ⁸Gleneagles Medical Centre, Singapore, SG, ⁹National University Cancer Institute, Singapore, Singapore, SG, ¹⁰National Cancer Center, Goyang, KR, ¹¹Asan Medical Center, Seoul, KR, ¹²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ¹³Puma Biotechnology Inc., Los Angeles, US, ¹⁴CANbridge Pharma, Taipei, TW

15:22 - 15:32 **Invited Discussant abstracts 450 and 460**

P. Francis, Peter MacCallum Cancer Centre, Melbourne, AU

15:32 - 15:42 **LIVE Q&A**

14:00 - 15:45 Type: Proffered Paper session Channel 2
Title: Proffered paper session on Gynaecological tumours
 Chair: Keiichi Fujiwara, JP

14:00 - 14:12 **2340 - Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1**

M. Friedlander¹, K. Moore², N. Colombo³, G. Scambia⁴, B.-G. Kim⁵, A. Oaknin⁶, A. Lisianskaya⁷, A. Floquet⁸, A. Leary⁹, G. Sonke¹⁰, C. Gourley¹¹, S. Banerjee¹², A. Oza¹³, A. González-Martín¹⁴, C. Aghajanian¹⁵, W. Bradley¹⁶, E. Holmes¹⁷, E. Lowe¹⁸, P. Disilvestro¹⁹, ¹Prince of Wales Hospital, Randwick, AU, ²Stephenson Oklahoma Cancer Center, Oklahoma City, US, ³University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, IT, ⁴Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, IT, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁶Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ⁷St Petersburg City Oncology Dispensary, St Petersburg, RU, ⁸Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Bordeaux, FR, ⁹Institut Gustave-Roussy, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Villejuif, FR, ¹⁰The Netherlands Cancer Institute, Amsterdam, NL, ¹¹Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, GB, ¹²The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, ¹³Princess Margaret Cancer Centre, Toronto, CA, ¹⁴Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Clínica Universidad de Navarra, Madrid, ES, ¹⁵Memorial Sloan Kettering Cancer Center, New York, US, ¹⁶Froedtert and the Medical College of Wisconsin, Milwaukee, US, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸AstraZeneca, Gaithersburg, US, ¹⁹Women & Infants Hospital, Providence, US

14:12 - 14:24 **2350 - Efficacy and safety of Niraparib in Chinese Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose: A**



Subgroup Analysis of A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

X. Wu¹, J. Zhu², R. Yin³, J. Yang⁴, J. Liu⁵, J. Wang⁶, L. Wu⁷, Z. Liu⁸, Y. Gao⁹, D. Wang¹⁰, G. Lou¹¹, H. Yang¹², Q. Zhou¹³, B. Kong¹⁴, Y. Huang¹⁵, L. Chen¹⁶, G. Li¹⁷, R. An¹⁸, K. Wang¹⁹, Y. Zhang²⁰, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Cancer hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, CN, ³West China Second University Hospital, Sichuan University, Chengdu, CN, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁵Sun Yat-sen University cancer center, Guangzhou, CN, ⁶Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ⁷National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁸The First Hospital of Jilin University, Changchun, CN, ⁹Peking University Cancer Hospital & Institute, Beijing, CN, ¹⁰Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, CN, ¹¹Harbin Medical University Cancer Hospital, Harbin, CN, ¹²The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Kunming, CN, ¹³Chongqing University Cancer Hospital, Chongqing, CN, ¹⁴Qilu Hospital of Shandong University, Qingdao, CN, ¹⁵Hubei Cancer Hospital, Wuhan, CN, ¹⁶Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, CN, ¹⁷Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ¹⁸The First Affiliated Hospital of Xi'an Jiaotong University, Xian, CN, ¹⁹Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ²⁰Xiangya Hospital, Central South University, Changsha, CN

14:24 - 14:36

2360 - Olaparib (ola) plus bevacizumab (bev) as maintenance (mx) therapy in patients (pts) with newly diagnosed advanced ovarian carcinoma (OC): Japan subset of the PAOLA-1 trial

K. Fujiwara¹, H. Fujiwara², H. Yoshida³, T. Satoh³, K. Yonemori⁴, S. Nagao⁵, T. Matsumoto⁶, H. Kobayashi⁷, H. Bourgeois⁸, P. Harter⁹, A.M. Mosconi¹⁰, I. Palacio¹¹, A. Reinthaller¹², T. Fujita¹³, R. Bloomfield¹⁴, E. Pujade-Lauraine¹⁵, I. Ray-Coquard¹⁶, ¹Saitama Medical University International Medical Center, Saitama, JP, ²Jichi Medical University Hospital, Tochigi, JP, ³University of Tsukuba Hospital, Ibaraki, JP, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Hyogo Cancer Center, Akashi, JP, ⁶Ehime University Hospital, Ehime, JP, ⁷Kagoshima University Hospital, Kagoshima, JP, ⁸Centre Jean Bernard - Clinique Victor Hugo, and GINECO, Le Mans, FR, ⁹Kliniken Essen Mitte, Essen, DE, ¹⁰Ospedale Santa Maria della Misericordia, Perugia, IT, ¹¹Hospital Universitario Central de Asturias, Oviedo, ES, ¹²Medical University Vienna, Vienna, AT, ¹³Astrazeneca, Osaka, JP, ¹⁴AstraZeneca, Cambridge, GB, ¹⁵Université Paris Descartes, Paris, FR, ¹⁶Centre Léon Bérard, Lyon, FR

14:36 - 14:48

Invited Discussant abstracts 2340, 2350 and 2360

N. Concin, Medical University of Innsbruck, Innsbruck, AT

14:48 - 14:58

LIVE Q&A

14:58 - 15:10

2370 - Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on



chemotherapy response score and recurrence for high-grade serous ovarian cancer patients with advanced disease

J. Li¹, M.-F. Wu², H. Li², Z.-Q. Lin², L.-J. Wang², ¹2nd Affiliated Hospital/Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, CN, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN

15:10 - 15:22 **2380 - Deep learning magnetic resonance imaging radiomic predict platinum-sensitive in patients with epithelial ovarian cancer**

L. Ruilin¹, Y. Yu¹, Q. Li¹, Y. Tan¹, Z.-Q. Lin², H. Yao¹, ¹2nd Affiliated Hospital/Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, CN, ²Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN

15:22 - 15:32 **Invited Discussant abstracts 2370 and 2380**

F. Peccatori, Istituto Europeo di Oncologia, Milan, IT

15:32 - 15:42 **LIVE Q&A**

14:00 - 15:35 Type: Proffered Paper session Channel 3
Title: Proffered paper and Mini oral mixed session on Head and neck
 Chair: Amanda Psyrrri, GR; Brigette Ma, HK

14:00 - 14:12 **2650 - Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial**

Y. Chi¹, M. Gao², Y. Zhang³, F. Shi⁴, Y. Cheng⁵, Z. Guo⁶, M. Ge⁷, J. Qin⁸, J. Zhang⁹, Z. Li¹⁰, X. Zhou¹¹, R. Huang¹², X. Chen¹³, H. Liu¹⁴, R. Cheng¹⁵, Z. Xu¹⁶, X. Zheng², D. Li¹⁷, P. Tang¹, ¹National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ³Jiangsu Cancer Hospital, Nanjing, CN, ⁴Hunan Cancer Hospital, Changsha, CN, ⁵Jilin Cancer Hospital, Changchun, CN, ⁶Sun Yat-sen University, Cancer Center, Guangzhou, CN, ⁷Zhejiang Cancer Hospital, Hangzhou, CN, ⁸Henan Cancer Hospital, Henan, CN, ⁹Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁰Tumor Hospital of China Medical University, Liaoning Tumor Hospital & Institute, Shenyang, CN, ¹¹Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing, CN, ¹²West China School of Medicine/West China Hospital, Sichuan University, Sichuan, CN, ¹³Beijing Tongren Hospital, Capital Medical University, Beijing, CN, ¹⁴Fujian Cancer Hospital, Fuzhou, CN, ¹⁵First Affiliated Hospital of Kunming Medical University, Kunming, CN, ¹⁶Cancer Hospital, Chinese Academy of Medical Science, Beijing, CN, ¹⁷Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, CN

14:12 - 14:24 **2660 - Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Updated efficacy and safety analysis of NCT03097939**

H.-F. Kao¹, M.-K. Ang², Q.S. Ng², D.S.W. Tan², W. Tan³, T. Rajasekaran³, A. Jain², B.-C.



Liao⁴, S.H. Tan³, E.-H. Tan², N.G. Iyer², M.L.K. Chua², R.-L. Hong⁴, D.W.-T. Lim²,
¹National Taiwan University Hospital, Taipei, TW, ²NCCS - National Cancer Centre
 Singapore, Singapore, SG, ³National Cancer Centre Singapore, Singapore, SG, ⁴National
 Taiwan University Hospital, New Taipei city, TW

- 14:24 - 14:36 **2670 - Distinct phenotypes of locoregionally advanced (LA-NPC) harbor disparate survival outcomes and are associated with germline variants**
 E. Ong¹, A. Sim¹, L. Huang², K.P. Low¹, W. Wai Yee¹, D. Susanti¹, H. Wang¹, T. Tan¹, K.W. Fong¹, Y.L. Soong¹, G.S. Tan³, T. Lim³, J. Wee¹, D. Lim¹, N.G. Iyer¹, J. Hwang³, M. Abazeed⁴, J.X. Bei⁵, M.L.K. Chua¹, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²Guangxi Medical University Cancer Hospital, China, CN, ³Singapore General Hospital, Singapore, SG, ⁴Northwestern University, IL, US, ⁵Center for Precision Medicine, Guangzhou, CN
- 14:36 - 14:48 **Invited Discussant abstracts 2650, 2660 and 2670**
 I. Tinhofer-Keilholz, Charité - Universitätsmedizin Berlin, Berlin, DE
- 14:48 - 14:58 **LIVE Q&A**
- 14:58 - 15:03 **268MO - A phase-Ib study of lucitanib (AL3810) in a cohort of patients with recurrent and metastatic nasopharyngeal carcinoma (NPC)**
 H.-Y. Zhao¹, Y. Zhang¹, Y.-X. Ma¹, L. Zhang¹, J. Lin², S. Qin³, ¹Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, CN, ²Oriental Hospital of Tongji University, Shanghai, CN, ³Nanjing Baiyi Hospital, Nanjing, CN
- 15:03 - 15:08 **269MO - Comparison of three induction chemotherapy regimens with gemcitabine plus cisplatin, cisplatin plus fluorouracil, and cisplatin plus capecitabine for locoregionally advanced nasopharyngeal carcinoma: A pooled analysis of two prospective studies**
 S.K. Chan¹, C.W. Choi², S.Y. Chan², C.C. Tong², K.O. Lam², D.L.W. Kwong², T.W. Leung², M.Y. Luk³, A.W.M. Lee², V.H.F. Lee², ¹The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, HK, ²The University of Hong Kong Li Ka Shing Faculty of Medicine, Pokfulam, HK, ³Queen Mary Hospital, Hong Kong, HK
- 15:08 - 15:13 **270MO - A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study**
 L. Zhang¹, Y. Yang¹, X. Chen², J. Li³, J. Pan⁴, X. He⁵, L. Lin⁶, Y. Shi⁷, W. Feng⁸, J. Xiong⁹, K. Yang¹⁰, Q. Yu¹¹, D. Hu¹², Y. Sun¹³, Q. Zhang¹⁴, G. Hu¹⁵, P. Li¹⁶, L. Shen¹⁷, Q. Yang¹⁸, B. Zhang¹⁸, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³Jiangxi Cancer Hospital, Nanchang, CN, ⁴Fujian Provincial Cancer Hospital, Fuzhou, CN, ⁵Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ⁶The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, ⁷Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ⁸Foshan First People's Hospital, Foshan, CN, ⁹The First Affiliated Hospital of Nanchang University, Nanchang,



CN, ¹⁰Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, CN, ¹¹Guangxi Medical University Affiliated Tumor Hospital, Nanning, CN, ¹²Hubei Cancer Hospital, Wuhan, CN, ¹³Beijing Cancer Hospital, Beijing, CN, ¹⁴Fudan University Shanghai Cancer Center, Shanghai, CN, ¹⁵Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ¹⁶West China Hospital of Sichuan University, Chengdu, CN, ¹⁷Xiangya Hospital Central South University, Changsha, CN, ¹⁸Jiangsu Hengui Medicine Co., Ltd., Shanghai, CN

15:13 - 15:21 **Invited Discussant abstracts 268MO, 269MO and 270MO**

E. Hui, The Chinese University of Hong Kong, Sha Tin, HK

15:21 - 15:29 **LIVE Q&A**

14:00 - 15:45 Type: Proffered Paper session Channel 4
Title: Proffered paper session on Haematological malignancies
 Chair: Koji Izutsu, JP; Wojciech Jurczak, PL

14:00 - 14:12 **2550 - Genetic mutations of Tim-3 ligand, and exhausted Tim-3+CD8+ T cells and survival in diffuse large B cell lymphoma**

X. Wang, T. Zhang, Y. Hong, X. Liu, L. Qiu, L. Li, Z. Qian, S. Zhou, B. Meng, Q. Zhai, H. Zhang, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN

14:12 - 14:24 **2560 - Associations of OX40 and tumour microenvironment with outcomes in diffuse large B-cell lymphoma**

X.-H. Wang¹, Y. Li¹, Y. Hong¹, X. Liu¹, L. Li¹, L. Qiu¹, Z. Qian¹, S. Zhou¹, L. Jiao², Q. Zhai¹, B. Meng¹, K. Fu³, H. Zhang¹, ¹Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ²Panovue Biological Technology Co., Ltd, Beijing, CN, ³University of Nebraska Medical Center, Omaha, US

14:24 - 14:34 **Invited Discussant abstracts 2550 and 2560**

L. Truemper, Universitätsmedizin Göttingen, Goettingen, DE

14:34 - 14:44 **LIVE Q&A**

14:44 - 14:56 **2570 - Intercontinental cooperative non-Hodgkin T-cell lymphoma prospective registry study in Asia: ICT study**

S.E. Yoon¹, S.J. Kim¹, D.H. Yoon², T.-Y. Chen³, Y. Koh⁴, K.W. Kang⁵, H.S. Lee⁶, K. Kuang Wei Tay⁷, S.T. Lim⁸, M. Poon⁹, C. Irawan¹⁰, W. Zhao¹¹, Y.R. Do¹², M.H. Lee¹³, S.C. Ng¹⁴, W.-S. Lee¹⁵, Y. Guo¹⁶, H. Zhang¹⁷, J. Zhu¹⁸, W.S. Kim¹, ¹Samsung Medical Center (SMC), Seoul, KR, ²Asan medical center, Seoul, KR, ³National Cheng Kung University Hospital, Tainan, TW, ⁴Seoul National University Hospital, Seoul, KR, ⁵Korea University Anam Hospital, Seoul, KR, ⁶Kosin University Gospel Hospital, Busan, KR, ⁷Oncocare cancer center, Singapore, SG, ⁸National Cancer Center Singapore, Singapore, SG, ⁹National University Hospital, Singapore, SG, ¹⁰Indonesia Cipto Mangunkusumo National Central



General Hospital, Indonesia, ID, ¹¹Ruijin Hospital, Shanghai, CN, ¹²Donsan Medical Center, Daegu, KR, ¹³Konkuk university Medical Center, Seoul, KR, ¹⁴Sime Darby Medical Center, Kuala Lumpur, MY, ¹⁵Busan Baik Hospital, Busan, KR, ¹⁶Fudan University Shanghai Cancer Center, Shanghai, CN, ¹⁷Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ¹⁸Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, CN

14:56 - 15:08 **2580 - A germline variant rs2736098 in the TERT gene is a novel predisposition allele associated with JAK2V617F-positive myeloproliferative neoplasms**

M.A.A. Maruf¹, K.H. Leung², S. Luo², C.L. Huang², S.P. Yip², ¹Hong Kong polytechnic university, Kowloon, HK, ²The Hong Kong polytechnic university, Kowloon, HK

15:08 - 15:20 **2590 - Treatment patterns and outcomes in older patients with mantle cell lymphoma in an Asian population**

X. Yang¹, L.P. Khoo², E.W.Y. Chang³, V.S. Yang³, E. Poon³, N. Somasundaram², M. Farid², T.P.L. Tang², M. Tao², S.T. Lim³, J.Y. Chan², ¹National University of Singapore, Singapore, SG, ²National Cancer Centre Singapore, Singapore, SG, ³National Cancer Center Singapore, Singapore, SG

15:20 - 15:32 **Invited Discussant abstracts 2570, 2580 and 2590**

S.T. Lim, National Cancer Center Singapore, Singapore, SG

15:32 - 15:42 **LIVE Q&A**

16:00 - 17:30 Type: Proffered Paper session Channel 1
Title: Proffered paper session on Thoracic cancers
 Chair: Linda Coate, IE

16:00 - 16:12 **LBA4 - GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)**

C. Zhou¹, Z. Wang², Y. Sun³, L. Cao⁴, Z. Ma⁵, R. Wu⁶, Y. Yu⁷, W. Yao⁸, J. Chang⁹, J. Chen¹⁰, W. Zhuang¹¹, J. Cui¹², X. Chen¹³, Y. Lu¹⁴, H. Shen¹⁵, P. Li¹⁶, J. Wang¹⁶, B. Sun¹⁶, D. Lu¹⁶, J. Yang¹⁶, ¹Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN, ²Beijing Cancer Hospital, Beijing, CN, ³Jinan central hospital, jinan, CN, ⁴Anhui Provincial Hospital, Hefei, CN, ⁵Henan Cancer Hospital, Zhengzhou, CN, ⁶Shengjing Hospital of China Medical University, Hua Xiang branch hospital, Shenyang, CN, ⁷Harbin Medical University Cancer Hospital, Harbin, CN, ⁸Sichuan Cancer Hospital & Institute, Chengdu, CN, ⁹1. Fudan University Shanghai Cancer Center, Shanghai 200032, China 2. Shanghai Medical College, Fudan University, Shanghai, 200032, China 3. Institute of Thoracic Oncology, Fudan University, Shanghai 200032, China, Shanghai, CN, ¹⁰Hunan Cancer Hospital, Changsha, CN, ¹¹Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ¹²First Hospital of Jilin University, Changchun, CN, ¹³Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ¹⁴West China Hospital, Chengdu, CN, ¹⁵2nd



Affiliated Hospital of Medical College of Zhejiang University, Zhejiang, CN, ¹⁶CStone Pharmaceuticals (Su Zhou) Co., Ltd, Suzhou, CN

- 16:12 - 16:24 **3750 - Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC**
M. Nishio¹, F. Barlesi², S. Ball³, R. Bordoni⁴, M. Cobo⁵, P. Dubray-Longeras⁶, J. Goldschmidt⁷, S. Novello⁸, F. Orlandi⁹, R. Sanborn¹⁰, Z. Szalai¹¹, G. Ursol¹², D. Mendus¹³, L. Wang¹⁴, X. Wen¹⁴, M. Mcclelland¹³, T. Hoang¹⁴, S. Phan¹⁴, M. Socinski¹⁵, ¹The Cancer Institute Hospital of JFCR, Tokyo, JP, ²Aix Marseille University, Marseille, FR, ³Barking, Havering & Redbridge University Hopsitals NHS Trust, Romford, GB, ⁴Northside Hospital Cancer Institute, Atlanta, US, ⁵Unidad de Gestión Clínica Intercentros de Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria. IBIMA. Málaga, Malaga, ES, ⁶Centre Jean Perrin, Clermont-Ferrand, FR, ⁷Blue Ridge Cancer Care, Blacksburg, US, ⁸Thoracic Oncology Unit AOU San Luigi, Orbassano, IT, ⁹Instituto Nacional del Torax, Santiago, CL, ¹⁰Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, US, ¹¹Petz Aladár County Teaching Hospital, Győr, HU, ¹²Acinus, Kropyvnytskyi, UA, ¹³Genentech, South San Francisco, US, ¹⁴Genentech, Inc., South San Francisco, US, ¹⁵AdventHealth Cancer Institute, Orlando, US
- 16:24 - 16:34 **Invited Discussant abstracts LBA4 and 3750**
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE
- 16:34 - 16:44 **LIVE Q&A**
- 16:44 - 16:56 **3760 - Randomized, multicenter trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small cell lung cancer: NCT01631357**
L. Liu¹, Q. Gao², J. Jiang³, J. Zhang⁴, X. Song⁵, J. Cui⁶, Y. Ye⁷, Z. Wang⁸, H. Yao⁵, X. Zhang¹, X. Hao¹, R. Xiubao⁹, ¹Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ²Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ³Third Affiliated Hospital of Soochow University, Changzhou, CN, ⁴Shanxi Bethune Hospital, Taiyuan, CN, ⁵Third Affiliated Hospital of Kunming Medical University, Kunming, CN, ⁶First Hospital of Jilin University, Changchun, CN, ⁷Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, CN, ⁸Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ⁹Tianjin Cancer Hospital, Tianjin, CN
- 16:56 - 17:08 **3770 - A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancer**
X. Ai¹, Y. Pan², J. Shi³, N. Yang⁴, C. Liu⁵, J. Zhou⁶, X. Zhang⁷, X. Dong⁸, J. He⁹, X. Li¹⁰, G. Chen¹¹, X. Li¹², H. Zhang¹³, W. Liao¹⁴, Y. Zhang¹⁵, Z. Ma¹⁶, B. Zhang¹⁷, D. Zhang¹⁷, S. Lu¹⁸, ¹Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ²Anhui Provincial Hospital, Hefei, CN, ³Linyi Cancer Hospital, Linyi, CN, ⁴Hunan Cancer Hospital, Changsha, CN, ⁵Cancer Hospital Affiliated to Xinjiang Medical University, Ürümqi, CN, ⁶First Affiliated Hospital, Zhejiang University, Hangzhou, CN, ⁷Nantong Tumor Hospital, Nantong, CN, ⁸Union hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ⁹The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ¹⁰Liaoning Cancer Hospital



& Institute, Shenyang, CN, ¹¹The Third Affiliated Hospital of Harbin Medical University, Harbin, CN, ¹²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ¹³Tangdu Hospital, Xi'an, CN, ¹⁴Department of Oncology, Guangzhou, CN, ¹⁵Zhejiang cancer hospital, Hangzhou, CN, ¹⁶Henan Cancer Hospital, Zhengzhou, CN, ¹⁷Zai Lab (Shanghai) Co., Ltd, Shanghai, CN, ¹⁸Shanghai Chest Hospital, Shanghai, CN

17:08 - 17:18 **Invited Discussant abstracts 3760 and 3770**

A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

17:18 - 17:28 **LIVE Q&A**

16:00 - 17:00 Type: Proffered Paper session Channel 2
Title: Proffered paper session on Genitourinary tumours
 Chair: Silke Gillessen, CH; Yuji Miura, JP

16:00 - 16:12 **1990 - A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis**

B. Szabados¹, A. Rodriguez-Vida², I. Duran³, S.J. Crabb⁴, M.S. Van Der Heijden⁵, A. Font Pous⁶, G. Gravis⁷, U. Anido Herranz⁸, A. Protheroe⁹, A. Ravaud¹⁰, D. Maillet¹¹, M.J. Mendez¹², C. Suarez¹³, M. Linch¹⁴, A. Prendergast¹⁵, C. Tyson¹, K. Mousa¹⁵, D. Castellano¹⁶, T. Powles¹⁷, ¹Barts Cancer Institute, London, GB, ²Hospital del Mar, Barcelona, ES, ³Instituto de Biomedicina de Sevilla, Seville, ES, ⁴Southampton Experimental Cancer Medicine Centre, Southampton, GB, ⁵Department of Medical Oncology, Amsterdam, NL, ⁶Catalan Institute of Oncology, Badalona, ES, ⁷institut Paoli-Calmettes, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, FR, ⁸Medical oncology, Bordeaux, FR, ⁹Churchill Hospital, Oxford, Oxford, FR, ¹⁰Hopital Saint-Andre, Bordeaux, FR, ¹¹Hospital Lyon Sud, Lyon, FR, ¹²Reina Sofia University Hospital, Cordoba, ES, ¹³Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁴University College London Cancer Institute, London, GB, ¹⁵Barts Experimental Cancer Medicine Centre, London, GB, ¹⁶Hospital 12 de Octubre, Madrid, ES, ¹⁷St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

16:12 - 16:24 **2000 - Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia**

C. Kondoh¹, W.K. Bae², S. Tamada³, N. Matsubara¹, H.J. Lee⁴, R. Mizuno⁵, S. Ani⁶, G. Kimura⁷, Y. Tomita⁸, C.-H. Chang⁹, J.W.-C. Chang¹⁰, J. Lin¹¹, R. Perini¹², L.R. Molife¹³, T. Powles¹⁴, B. Rini¹⁵, H.-J. Chung¹⁶, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, KR, ³Osaka City University Hospital, Osaka, JP, ⁴Chungnam National University School of Medicine, Daejeon, KR, ⁵Keio University Hospital, Tokyo, JP, ⁶Nara Medical University Hospital, Nara, JP, ⁷Nippon Medical School Main Hospital, Tokyo, JP, ⁸Niigata University Medical & Dental Hospital, Niigata, JP, ⁹China Medical University Hospital, Taichung, TW, ¹⁰Chang Gung Medical Foundation-Linkou, Taoyuan, TW, ¹¹Merck & Co., Inc., Kenilworth, US, ¹²Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹³MSD UK, London, GB, ¹⁴St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ¹⁵Cleveland Clinic Taussig Cancer Institute, Cleveland, US, ¹⁶Taipei



Veterans General Hospital, Taipei City, TW

- 16:24 - 16:36 **2170 - Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study**
A.M. Joshua¹, H. Gurney², M. Retz³, A. Tafreshi⁴, P.C.C. Fong⁵, N.D. Shore⁶, E. Romano⁷, M. Augustin⁸, J.M. Piulats⁹, W.R. Berry¹⁰, M.P. Kolinsky¹¹, S.S. Sridhar¹², H.J. Conter¹³, T. Todenhöfer¹⁴, L.J. Appleman¹⁵, H. Wu¹⁶, C. Schloss¹⁶, C.H. Poehlein¹⁶, J.S. De Bono¹⁷, E.Y. Yu¹⁸, ¹Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, AU, ²The Crown Princess Mary Cancer Centre, Westmead, AU, ³University Rechts der Isar Hospital, Technical University of Munich, Munich, DE, ⁴Consulting Suites, Wollongong, AU, ⁵Auckland City Hospital, Auckland, NZ, ⁶Carolina Urologic Research Center, Myrtle Beach, US, ⁷Institut Curie, Paris, FR, ⁸Klinikum Nuernberg Nord, Nürnberg, DE, ⁹Catalan Cancer Institute, Barcelona, ES, ¹⁰Duke Cancer Center Cary, Cary, US, ¹¹Cross Cancer Institute, Edmonton, CA, ¹²UHN Princess Margaret Cancer Centre, Toronto, CA, ¹³University of Western Ontario, Brampton, CA, ¹⁴Universitaets-Hautklinik Tuebingen, Tuebingen, DE, ¹⁵UPMC, Pittsburgh, US, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷The Royal Marsden NHS Foundation Trust, London, GB, ¹⁸University of Washington, Seattle, US
- 16:36 - 16:48 **Invited Discussant abstracts 1990, 2000 and 2170**
Y. Miura, Toranomom Hospital, Tokyo, JP
- 16:48 - 16:58 **LIVE Q&A**
- 16:00 - 17:00 Type: Proffered Paper session Channel 3**
Title: Proffered paper session on Gastrointestinal tumours
 Chair: Su Pin Choo, SG; Kohei Shitara, JP
- 16:00 - 16:12 **LBA2 - Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2**
Z. Ren¹, J. Fan¹, J. Xu², Y. Bai³, A. Xu⁴, S. Cang⁵, C. Du⁶, B. Liu⁷, Q. Li⁸, Y. Lu⁹, Y. Chen¹⁰, G. Shao¹¹, Y. Guo¹², Z. Chen¹³, Y. Yang¹⁴, M. Chen¹⁴, Y. Wang¹⁴, H. Zhou¹⁴, ¹Zhongshan hospital of fudan university, Shanghai, CN, ²The 5th Medical Center of PLA General Hospital, Beijing, CN, ³Harbin Medical University Cancer Hospital, Harbin, CN, ⁴Nantong Tumor Hospital, Nantong, CN, ⁵Henan Provincial People's Hospital, Zhengzhou, CN, ⁶The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN, ⁷Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN, ⁸West China Hospital, Sichuan University, Chengdu, CN, ⁹The Fifth Medical Center of PLA General Hospital, Beijing, CN, ¹⁰Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou, CN, ¹¹Zhejiang Cancer Hospital, Hangzhou, CN, ¹²Nan Fang Hospital, Guangzhou, CN, ¹³The Second Hospital of Anhui Medical University, Hefei, CN, ¹⁴Innovent Biologics, Inc., Suzhou, CN
- 16:12 - 16:24 **1140 - Assessment of robotic versus laparoscopic distal gastrectomy for gastric cancer: A randomized controlled trial**



J. Lu, D. Wu, H.-G. Wang, C.-H. Zheng, P. Li, J.-W. Xie, J.-B. Wang, J.-X. Lin, Q.-Y. Chen, L.-L. Cao, M. Lin, R.-H. Tu, Z.-N. Huang, J.-L. Lin, H.-L. Zheng, C. Huang, Fujian Medical University Union Hospital, Fuzhou, CN

16:24 - 16:36 **790 - Clinical performance of Immunoscore[®] in early colon cancer in the Asian population**

J. Galon¹, Y. Kawakami², T. Torigoe³, Y. Wang⁴, P. Patel⁵, H. Vora⁵, B. Mlecnik⁶, F. Marliot⁷, C. Bifulco⁸, A. Lugli⁹, I. Nagtegaal¹⁰, A. Hartmann¹¹, M. Van Den Eynde¹², M. Roehrl¹³, P. Ohashi¹³, E. Zavadova¹⁴, F. Marincola¹⁵, P. Ascierto¹⁶, B.A. Fox¹⁷, F. Pagès¹, ¹Laboratory of Integrative Cancer Immunology, Paris, FR, ²Keio University School of Medicine, Tokyo, JP, ³Sapporo Medical University School of Medicine, Sapporo, JP, ⁴Health Science Center of Xi'an Jiaotong University, Xian, CN, ⁵The Gujarat Cancer and Research Institute, Asarwa Ahmedabad, IN, ⁶INSERM, Paris, FR, ⁷Hôpital Européen Georges Pompidou, Paris, FR, ⁸Providence Portland Medical Center, Portland, US, ⁹University of Bern, Bern, CH, ¹⁰Radboud University Medical Center, Nijmegen, NL, ¹¹Universitätsklinikum Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, DE, ¹²Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, BE, ¹³University Health Network, Toronto, CA, ¹⁴First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, CZ, ¹⁵Refuge Biotechnologies, Menlo Park, US, ¹⁶Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁷Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US

16:36 - 16:48 **Invited Discussant abstracts LBA2, 1140 and 790**

S. Lonardi, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

16:48 - 16:58 **LIVE Q&A**

16:00 - 17:20 Type: Proffered Paper session Channel 4
Title: Proffered paper session on SARS and Covid19
 Chair: Emanuela Romano, FR

16:00 - 16:12 **3180 - Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients**

D. Pinato¹, A. Zambelli², A. Bertuzzi³, A. Marrari³, N. Saoudi-Gonzalez⁴, O. Mirallas⁴, M. Galazi⁵, D. Generali⁶, S. Grisanti⁷, C. Tondini⁸, A. Prat⁹, J. Tabernero¹⁰, R. Mesia¹¹, R. Salazar¹², A. Sureda¹², M. Franchi², L. Chiudinelli², D.G. Illescas¹⁰, M. Libertini¹³, A. Gennari¹⁴, ¹Imperial College London - Hammersmith Hospital, London, GB, ²Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, ³Humanitas Cancer Centre, Milan, IT, ⁴Vall D'Hebron Hospital, Barcelona, ES, ⁵University College London NHS Trust, London, GB, ⁶ASST Cremona, Cremona, IT, ⁷Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT, ⁸Ospedali Riuniti di Bergamo, Bergamo, IT, ⁹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Catalan Institute of Oncology, Badalona, ES, ¹²Institut Català d'Oncologia-Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ¹³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹⁴University of Eastern Piedmont, Novara, IT



- 16:12 - 16:27 **Invited Discussant 3180 and presentation: Cancer and Covid registries, what did we learn on prognosticators and outcomes? The way forward**
J. Whisenant, Vanderbilt Ingram Cancer Center, Nashville, US
- 16:27 - 16:37 **LIVE Q&A**
- 16:37 - 16:49 **3190 - The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection**
G. Dettoni¹, N. Diamantis², A. Loizidou³, M. Piccart⁴, J. Chester⁵, A. Jackson⁵, V. Tovazzi⁶, V. Fotia⁷, A. Sita-Lumsden⁸, M. Bower⁹, G. Gaidano¹⁰, E. Felip¹¹, D. Ottaviani¹², C. Sng¹², L. Rimassa¹³, A. Santoro¹³, J. Aguilar-Company¹⁴, E. Seguí¹⁵, S. Dolly⁸, D. Pinato¹⁶, ¹Imperial College London - Hammersmith Hospital, London, GB, ²Barts Health NHS Trust, London, GB, ³Jules Bordet Institute, Brussels, BE, ⁴Institut Jules Bordet, Brussels, BE, ⁵Velindre Cancer Centre, Cardiff, GB, ⁶Spedali Civili di Brescia, Brescia, IT, ⁷ASST Papa Giovanni XXIII, Bergamo, IT, ⁸Guy's and St Thomas' NHS Foundation Trust, London, GB, ⁹Chelsea & Westminster Hospital, London, GB, ¹⁰University of Piemonte Orientale "Amedeo Avogadro", Novara, IT, ¹¹Catalan Institute of Oncology, Badalona, ES, ¹²University College London Hospitals, London, GB, ¹³Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Milan, IT, ¹⁴Vall d'Hebron University Hospital, Barcelona, ES, ¹⁵Hospital Clinic, Barcelona, ES, ¹⁶Imperial College London, London, GB
- 16:49 - 17:04 **Invited Discussant 3190 and presentation: Biology of COVID19 infection in cancer patients and emerging biomarkers: Promises for tailoring management**
L. Castelo-Branco, Hospital Distrital de Faro, Faro, PT
- 17:04 - 17:14 **LIVE Q&A**



17:35 - 19:05	Type: ESMO Colloquium Title: ESMO Colloquium supported by GSK: Breakthroughs in molecular profiling and systemic therapies of endometrial and ovarian cancer	Channel 2
	Chair: Mansoor Raza Mirza, DK; Jonathan Ledermann, GB	
17:35 - 17:50	Molecular profiles of “actionable” aberrations in endometrial and ovarian cancer: The dawn of precision medicine	
	<u>I. Romero</u> , IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES	
17:50 - 18:05	The promise of immune checkpoint inhibitors in endometrial cancer	
	<u>A. Oaknin</u> , Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES	
18:05 - 18:20	Treatment benefit from PARP inhibitors and resistance mechanisms in patients with advanced epithelial ovarian cancer: State of the art and new concepts	
	<u>M.R. Mirza</u> , Copenhagen University Hospital, Copenhagen, DK	
18:20 - 18:35	Emerging combinations of immune checkpoint inhibitors with targeted agents in ovarian and endometrial carcinomas	
	<u>A.J. Gonzalez Martin</u> , Clinica Universidad de Navarra, Madrid, ES	
18:35 - 18:45	Key messages and wrap up	
	<u>J. Ledermann</u> , UCL Cancer Institute - UCL - London's Global University, London, GB	
18:45 - 19:05	Live Q&A	



17:35 - 19:05 **Type: ESMO Colloquium** **Channel 3**
Title: ESMO Colloquium supported by Astellas Pharma Singapore Pte. Ltd.: Optimising outcomes of patients with advanced prostate and urothelial cancer
 Chair: Ravindran Kanesvaran, SG; Karim Fizazi, FR

17:35 - 17:50 **Optimal combinations of systemic therapies in treatment-naïve patients with advanced hormone-sensitive prostate cancer: Which ones and for which patients?**
A. Stenzl, Eberhard Karls University, Tuebingen, DE

17:50 - 18:05 **How do modern first-line combination regimens affect the therapeutic algorithm in later lines of therapy in metastatic prostate cancer?**
K. Fizazi, Institut Gustave Roussy, Villejuif, FR

18:05 - 18:20 **State of the art therapeutic landscape in non-metastatic castration-resistant prostate cancer**
W.K. Kwong, HK IOC - Hong Kong Integrated Oncology Center, Hong Kong, HK

18:20 - 18:35 **Emerging systemic therapies in unresectable bladder cancer: Immunotherapy, kinase inhibitors and antibody-drug conjugates**
M. Galsky, Icahn School of Medicine at Mount Sinai Hospital, New York, US

18:35 - 19:05 **Q&A, live discussion and wrap up**

19:30 - 21:00 **Type: Special Session** **Channel 1**
Title: Joint SITC-ESMO Immunotherapy Primer 2
 Chair: Dawakar Davar, US

19:30 - 19:50 **Innate agonists in cancer immunotherapy: Part 1**
J. Luke, University of Pittsburgh Cancer Institute, Pittsburgh, US

19:50 - 20:10 **Innate agonists in cancer immunotherapy: Part 2**
D. Davar, University of Pittsburgh Cancer Institute, Pittsburgh, US

20:10 - 20:30 **Oncolytic viruses in cancer immunotherapy**
D. Zamarin, Memorial Sloan Kettering Cancer Center, New York, US

20:30 - 21:00 **Live Q&A and live discussion**



22-11-2020

12:00 - 13:30	Type: Industry Satellite Symposium Title: Amgen - Targeting the undruggable in KRAS-mutated advanced NSCLC and mCRC Chair: Ross A. Soo, SG	Channel 1
----------------------	--	------------------

12:00 - 12:10 **Welcome and introduction**
R. Soo, NCIS - National University Cancer Institute Singapore, Singapore, SG

12:10 - 12:30 **The role of KRAS as a molecular driver in advanced NSCLC and mCRC**
Y. Yatabe, National Cancer Center Hospital, Tokyo, JP

12:30 - 12:50 **Changing the course for KRAS-mutated advanced NSCLC**
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

12:50 - 13:10 **Changing the course for KRAS-mutated metastatic CRC**
T. Price, The Queen Elizabeth Hospital - Emergency Department, Woodville, AU

13:10 - 13:30 **Panel discussion**
R. Soo¹, Y. Yatabe², T.S.K. Mok³, T. Price⁴, ¹NCIS - National University Cancer Institute Singapore, Singapore, SG, ²National Cancer Center Hospital, Tokyo, JP, ³Prince of Wales Hospital, Shatin, HK, ⁴The Queen Elizabeth Hospital - Emergency Department, Woodville, AU



12:00 - 13:30	Type: Industry Satellite Symposium Title: Merck - Getting ahead in SCCHN: Dynamic treatment options with cetuximab	Channel 2
Chair: Makoto Tahara, JP		
12:00 - 12:05	Starting from the top: Welcome and introduction	
M. Tahara, National Cancer Center Hospital East, Kashiwa, JP		
12:05 - 12:20	Putting your heads together: Working with patients to establish tailored treatment goals in SCCHN	
D. Arya ¹ , M. Tahara ² , ¹ MAX Super Speciality Hospital, Saket in Saket, New Delhi, IN, ² National Cancer Center Hospital East, Kashiwa, JP		
12:20 - 12:45	Heading the right way: Treatment options with cetuximab (Erbix) in SCCHN	
D. Arya ¹ , J. Guigay ² , Y. Guo ³ , ¹ MAX Super Speciality Hospital, Saket in Saket, New Delhi, IN, ² Centre Anticancer Antoine Lacassagne, Nice, FR, ³ Fudan University Shanghai Cancer Center, Shanghai, CN		
12:45 - 13:10	Right patient, right treatment, right time: Treatment sequencing in R/M SCCHN	
J.C.-H. Hsieh ¹ , J. Guigay ² , ¹ Chang Gung Memorial Hospital-Linkou, Taoyuan, TW, ² Centre Anticancer Antoine Lacassagne, Nice, FR		
13:10 - 13:15	Looking ahead: Conclusions and future directions	
M. Tahara, National Cancer Center Hospital East, Kashiwa, JP		
13:15 - 13:30	Live panel discussion and Q&A	
Y. Guo, Fudan University Shanghai Cancer Center, Shanghai, CN		



12:00 - 13:30	Type: Industry Satellite Symposium Title: Boehringer Ingelheim - Treatment Considerations for Advanced NSCLC: Now and in the Future Chair: Byoung Cho, KR	Channel 3
12:00 - 12:05	Introduction <u>B. Cho</u> , Yonsei University College of Medicine, Seoul, KR	
12:05 - 12:20	Navigating first-line treatment decisions for EGFRM+ NSCLC: Extrapolating from Asian clinical trial experience <u>J.W.-C. Chang</u> , Chang Gung Medical Foundation-Linkou, Taoyuan, TW	
12:20 - 12:35	Tackling Uncommon EGFR mutations: Efficacy of EGFR TKIs in NSCLC <u>H. Tanaka</u> , Niigata Cancer Center Hospital, Niigata, JP	
12:35 - 12:50	KRAS-mutant NSCLC treatment advances on the horizon <u>B. Cho</u> , Yonsei University College of Medicine, Seoul, KR	
12:50 - 13:00	Closing <u>B. Cho</u> , Yonsei University College of Medicine, Seoul, KR	
13:00 - 13:30	Live Q&A <u>B. Cho</u> ¹ , <u>J.W.-C. Chang</u> ² , <u>H. Tanaka</u> ³ , ¹ Yonsei University College of Medicine, Seoul, KR, ² Chang Gung Medical Foundation-Linkou, Taoyuan, TW, ³ Niigata Cancer Center Hospital, Niigata, JP	



12:00 - 13:30	Type: Industry Satellite Symposium Title: Servier - Optimization of treatment strategy in advanced pancreatic cancer for Asian patients	Channel 4
Chair: Julien Taieb, FR; Katsuhiko Uesaka, JP		
12:00 - 12:05	Introduction <u>K. Uesaka</u> , Shizuoka Cancer Center, Shizuoka, JP	
12:05 - 12:20	From guidelines to daily practice: The European experience <u>S. Lonardi</u> , IOV - Istituto Oncologico Veneto IRCCS, Padova, IT	
12:20 - 12:35	Pancreatic cancer in Japan: from the current to the potential future treatment landscape <u>M. Ikeda</u> , National Cancer Center Hospital East, Kashiwa, JP	
12:35 - 12:50	From current to potential pancreatic cancer treatment landscape in China <u>L. Wang</u> , Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN	
12:50 - 13:05	Experience from daily practice with a new treatment option in Korea <u>C. Yoo</u> , Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR	
13:05 - 13:25	Live panel discussion: Practice sharing from Europe to Asia <u>J. Taieb</u> ¹ , <u>K. Uesaka</u> ² , <u>S. Lonardi</u> ³ , <u>M. Ikeda</u> ⁴ , <u>L. Wang</u> ⁵ , <u>C. Yoo</u> ⁶ , ¹ Hopital European George Pompidou, Paris, FR, ² Shizuoka Cancer Center, Shizuoka, JP, ³ IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴ National Cancer Center Hospital East, Kashiwa, JP, ⁵ Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN, ⁶ Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR	
13:25 - 13:30	Conclusions <u>J. Taieb</u> , Hopital European George Pompidou, Paris, FR	



14:00 - 15:20 **Type: Educational session** **Channel 1**
Title: New treatment paradigms in the treatment of locoregionally advanced nasopharyngeal cancer
 Chair: Amanda Psyrrri, GR; Boon-Cher Goh, SG

14:00 - 14:20 **Optimized chemoradiation treatment strategy for the management of locally advanced nasopharyngeal carcinoma**
J. Ma, Ningxia People's Hospital, Yinchuan, CN

14:20 - 14:40 **Optimizing therapeutic effect of concurrent chemotherapy by incorporating immunotherapy for locoregionally advanced NPC: Recent developments and biomarkers**
B. Ma, The Chinese University of Hong Kong, Sha Tin, HK

14:40 - 15:00 **Beyond immune-checkpoint inhibitors in the management of advanced NPC**
B.-C. Goh, National University Cancer Institute Singapore (NCIS), Singapore, SG

15:00 - 15:15 **LIVE Q&A**

14:00 - 15:20 **Type: Educational session** **Channel 2**
Title: How can we wisely incorporate immunotherapy in the clinic
 Chair: Seock-Ah Im, KR; Evandro de Azambuja, BE

14:00 - 14:20 **Immune-checkpoint inhibitors for metastatic breast cancer**
J. Tsurutani, Showa University, Shinagawa-ku, JP

14:20 - 14:40 **Incorporation of immunotherapy in neoadjuvant setting**
S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

14:40 - 15:00 **Refining patient selection: PDL1 and beyond**
F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

15:00 - 15:15 **LIVE Q&A**



14:00 - 15:20 **Type: Educational session** **Channel 3**
Title: Treatment of endometrial cancer in 2020 (including Guidelines)
 Chair: Keiichi Fujiwara, JP; Ignace Vergote, BE

14:00 - 14:15 **Surgical issues in the treatment of endometrial cancer**
J.-Y. Lee, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, KR

14:15 - 14:30 **The role of radiation treatments for endometrial cancer**
C. Creutzberg, Leiden University Medical Center (LUMC), Leiden, NL

14:30 - 14:45 **New molecular classification for endometrial cancer and its implications**
K. Hasegawa, Saitama Medical University International Medical Center, Hidaka, JP

14:45 - 15:00 **Perspectives in systemic therapy**
M. Friedlander, Prince of Wales Hospital, Randwick, AU

15:00 - 15:15 **LIVE Q&A**

14:00 - 15:20 **Type: Educational session** **Channel 4**
Title: Metastasis to the central nervous system
 Chair: Yong-Kil Hong, KR; Carmen Balana, ES

14:00 - 14:15 **Solid brain metastasis: Surgical approaches**
Y.-K. Hong, The Catholic University of Korea - College of Medicine - Songeui Medical Campus, Seoul, KR

14:15 - 14:30 **Solid brain metastasis: The role of radiotherapy**
K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

14:30 - 14:45 **Up-front metastasis in patients with oncogenic driver**
C. Balana, ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES

14:45 - 15:00 **Leptomeningeal metastasis**
U. Herrlinger, Institute of Experimental Immunology - UKB University of Bonn, Bonn, DE

15:00 - 15:15 **LIVE Q&A**



14:00 - 15:20 **Type: Educational session** **Channel 5**
Title: The role of antiangiogenics in sarcoma
 Chair: Paolo G. Casali, IT; Jean-Yves Blay, FR

14:00 - 14:15 **Antiangiogenics in alveolar soft part sarcomas**

H. Loong, The Chinese University of Hong Kong, Shatin, HK

14:15 - 14:30 **Antiangiogenics in extraskeletal myxoid chondrosarcoma**

S. Stacchiotti, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

14:30 - 14:45 **Antiangiogenics in solitary fibrous tumors**

J. Martin Broto, Hospital Universitario Virgen del Rocio, Seville, ES

14:45 - 15:00 **Antiangiogenics in GIST**

C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

15:00 - 15:15 **LIVE Q&A**

15:35 - 16:55 **Type: Educational session** **Channel 1**
Title: Update on hepatocellular carcinoma (HCC) and gastric cancer
 Chair: Arndt Vogel, DE; Su Pin Choo, SG

15:35 - 15:50 **Logoregional therapy in HCC: When to start and when to stop**

S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG

15:50 - 16:05 **Updates on systemic therapy in advanced HCC and optimal sequencing**

A. Vogel, Hannover Medical School, Hannover, DE

16:05 - 16:20 **Pre-, peri- and postoperative treatment: A three-way tie for resectable gastric cancer**

K. Muro, Aichi Cancer Center Hospital, Nagoya, JP

16:20 - 16:35 **Immunotherapy and new molecular options in gastric cancer**

A. Zaanan, Hopital European George Pompidou, Paris, FR

16:35 - 16:50 **LIVE Q&A**



15:35 - 16:55 **Type: Educational session** **Channel 2**
Title: The treatment of ovarian cancer in 2020
 Chair: Domenica Lorusso, IT; Jae-Weon Kim, KR

15:35 - 15:50 **Role of surgery and intraperitoneal hyperthermic chemoperfusion (HIPEC) in ovarian cancer**

J.-W. Kim, Seoul National University Hospital, Seoul, KR

15:50 - 16:05 **How PARP inhibitors change the first-line ovarian cancer treatment**

I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

16:05 - 16:20 **The role of homologous recombination deficiency (HRD) and its clinical implication: Do we need it?**

D.S. Tan, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

16:20 - 16:35 **Perspectives in ovarian cancer treatment (immunotherapy focus)**

D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT

16:35 - 16:50 **LIVE Q&A**

15:35 - 16:55 **Type: Educational session** **Channel 3**
Title: Contemporary approach to the management of oropharyngeal cancer
 Chair: Amanda Psyrrri, GR; Bhumsuk Keam, KR

15:35 - 15:50 **Management of early oropharyngeal cancer: Staging and surgical advances**

C. Simon, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

15:50 - 16:05 **Management of oropharyngeal cancer: Advances in radiation therapy**

M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

16:05 - 16:20 **Management in the first-line treatment of recurrent/ metastatic disease: Recent advances in immunotherapy and biomarkers**

A. Psyrrri, Attikon University Hospital, Athens, GR

16:20 - 16:35 **Refractory disease: New molecular targets and new drugs**

C. Le Tourneau, Institut Curie, Paris, FR

16:35 - 16:50 **LIVE Q&A**



15:35 - 16:55 **Type: Educational session** **Channel 4**
Title: Who can treat cancer patients? The status of medical oncology recognition in the Asia-Pacific region
 Chair: Elene Mariamidze, GE; Susie Stanway, GB

15:35 - 15:38 **Live introduction**

15:38 - 15:53 **WHO overview of oncology workforce in the Asian Pacific region**
A. Ilbawi, WHO - World Health Organization, Geneva, CH

15:53 - 16:08 **A success story calling the recognition of the profession of medical oncology in EU**
P.G. Casali, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

16:08 - 16:23 **Who can treat cancer patients? The example of Singapore**
R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

16:23 - 16:38 **Who can treat cancer patients? The example of India**
G.S. Bhattacharyya, G M Cancer Research Trust Palliative Care Unit, Salt Lake City Medical Center,, Kolkata, IN

16:38 - 16:50 **LIVE Q&A**



15:35 - 16:55	Type: Young Oncologist session Title: Vesalius talk: The importance of mentorship at all points of your career	Channel 5
Chair: Teresa Amaral, DE; Anna Sophie Berghoff, AT		
15:35 - 15:40	The importance of mentorship from a Young Oncologist perspective <u>T. Amaral</u> , University Hospital Tübingen, Tübingen, DE	
15:40 - 15:45	The importance of mentorship from a tertiary center perspective <u>A.S. Berghoff</u> , Medizinische Universität Wien (Medical University of Vienna), Vienna, AT	
15:45 - 15:50	The importance of mentorship from W4O perspective <u>J.W.-H. Tsang</u> , HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK	
15:50 - 15:55	The importance of mentorship from a LGP participant perspective <u>R. Wong</u> , Eastern Health - Box Hill Hospital - Main Entrance, Box Hill, AU	
15:55 - 16:55	Live Q&A and live discussion	



17:10 - 18:30 **Type: Educational session** **Channel 1**
Title: Urothelial cancer
 Chair: Thomas Powles, GB; Wai Kay Kwong, HK

17:10 - 17:15 **Presentation of case on non-muscle invasive bladder cancer (NMIBC)**
W.K. Kwong, HK IOC - Hong Kong Integrated Oncology Center, Hong Kong, HK

17:15 - 17:30 **Challenges and new options in the management of NMIBC**
E. Chiong, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG

17:30 - 17:35 **Presentation of a case: Metastatic urothelial carcinoma (mUC)**
W.K. Kwong, HK IOC - Hong Kong Integrated Oncology Center, Hong Kong, HK

17:35 - 17:50 **The evolving landscape in the frontline management of mUC**
T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

17:50 - 18:05 **Second-line mUC management: New standards and sequencing strategies**
M. Galsky, Icahn School of Medicine at Mount Sinai Hospital, New York, US

18:05 - 18:10 **Summary**
T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

18:10 - 18:25 **LIVE Q&A**

17:10 - 18:30 **Type: Educational session** **Channel 2**
Title: Follow-up care practices in cancer survivorship
 Chair: Christina Ruhlmann, DK; Florian Scotté, FR

17:10 - 17:30 **Follow-up care models: What are the international advances?**
R. Chan, Queensland University of Technology, Brisbane, AU

17:30 - 17:50 **Addressing the needs of cancer survivors: The paediatric and AYA perspective**
C. Yin Ting, The Chinese University of Hong Kong, Hong Kong, HK

17:50 - 18:10 **Management of late side-effects in cancer survivorship (including Guidelines)**
K. Jordan, University of Heidelberg, Heidelberg, DE

18:10 - 18:25 **LIVE Q&A**



17:10 - 18:30 **Type: Educational session** **Channel 3**
Title: Targeting the microenvironment in lymphomas and beyond
 Chair: Wojciech Jurczak, PL; Ranjana Advani, US

17:10 - 17:25 **Hodgkin lymphoma**
R. Advani, Stanford University School of Medicine, Stanford, US

17:25 - 17:40 **Follicular lymphoma**
C. Buske, Ulm Medical University, Ulm, DE

17:40 - 17:55 **Peripheral T cell lymphoma: CHOP and beyond?**
F. D'Amore, Aarhus University Hospital, Aarhus, DK

17:55 - 18:10 **Mantle cell lymphoma: No more chemotherapy?**
W.S. Kim, Samsung Medical Center (SMC), Seoul, KR

18:10 - 18:25 **LIVE Q&A**



17:10 - 18:30	Type: Collaborative session Title: Geriatric oncology in Asia: The silver tsunami is here, are we ready? (in collaboration with SIOG)	Channel 4
Chair: Christopher Steer, AU; Ravindran Kanesvaran, SG		
17:10 - 17:13	Introduction: Case study of older adult with cancer (lung or breast) <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
17:13 - 17:25	Geriatric oncology clinic in a high-income country (HIC) in Europe: Belgium <u>H. Wildiers</u> , University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
17:25 - 17:37	Geriatric oncology clinic in a HIC in Asia: South Korea <u>J.H. Kim</u> , Seoul National University Bundang Hospital, Seongnam, KR	
17:37 - 17:49	Geriatric oncology in low and middle income (LMIC) in Asia: Can it be done? <u>V. Noronha</u> , Tata Memorial Hospital, Mumbai, IN	
17:49 - 18:01	The nuts and bolts of supportive care for older adults with cancer <u>C. Steer</u> , Border Medical Oncology, East Albury, AU	
18:01 - 18:13	Geriatric principles for all oncologists <u>H. Lane</u> , Sir Charles Gairdner Hospital, Nedlands, AU	
18:13 - 18:25	Live Q&A and live discussion	



17:10 - 18:10 **Type: Special Session** **Channel 5**
Title: Artificial intelligence (AI)
 Chair: Fatima Cardoso, PT

- 17:10 - 17:12 **Open and welcome**
F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT
- 17:12 - 17:31 **AI-based surgery: The future is now**
P. Gouveia, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT
- 17:31 - 17:50 **The role of radiomics**
A. Tagliafico, IRCCS Ospedale Policlinico San Martino, Genova, IT
- 17:50 - 18:09 **The role of AI in oncology drug development**
S. Srihari, QIMR Berghofer Medical Research Institute, Brisbane, AU
- 18:09 - 18:10 **Closing remarks and conclusions**
F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT

18:45 - 19:50 **Type: Mini Oral session** **Channel 1**
Title: Mini oral session on Gastrointestinal tumours 2
 Chair: Julien Taieb, FR

- 18:45 - 18:50 **80MO - Gut microbiome analysis for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer patients**
Y. Yi, L. Shen, W. Shi, F. Xia, H. Zhang, Y. Wang, J. Zhang, Y. Wang, X. Sun, Z. Zhang, W. Zou, W. Yang, L. Zhang, Y. Ma, Z. Zhang, Fudan University Shanghai Cancer Center, Shanghai, CN
- 18:50 - 18:55 **81MO - Clinical experience of a personalized and tumour-informed circulating tumour DNA assay for minimal residual disease detection in oligometastatic colorectal cancer patients**
S. Cohen¹, N. Hook², S. Krinshpun², L. Westbrook², K. Loranger², J. Wallace², S. Sharma², A. Aleshin², P. Billings², ¹University of Washington School of Medicine, Seattle, US, ²Natera, Inc., San Carlos, US
- 18:55 - 19:00 **82MO - Automatical risk stratifying for colorectal cancer by deep learning based pathological score**
S. Chen¹, M. Zhang¹, J. Wang¹, M. Xu¹, W. Hu¹, L. Wee², W. Sheng¹, A. Dekker², Z. Zhang¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Maastricht University, Maastricht, NL
- 19:00 - 19:08 **Invited Discussant abstracts 80MO, 81MO and 82MO**
D.Q.Q. Chong, NCCS - National Cancer Centre Singapore, Singapore, SG



19:08 - 19:16 **LIVE Q&A**

19:16 - 19:21 **83MO - AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial**

J. Strickler¹, M. Fakih², T. Price³, J. Desai⁴, G. Durm⁵, J. Krauss⁶, Y. Kuboki⁷, T.W. Kim⁸, A. Sacher⁹, H. Henary¹⁰, J. Kim¹⁰, D. Hong¹¹, ¹Duke Cancer Center, Durham, US, ²City of Hope, Duarte, US, ³The Queen Elizabeth Hospital - Emergency Department, Woodville, AU, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵Division of Hematology/Oncology,, Indianapolis, US, ⁶University of Michigan, Michigan, US, ⁷Cancer Institute Hospital of JFCR, Tokyo, JP, ⁸Asan Medical Centre, University of Ulsan College of Medicine, Seoul, KR, ⁹Princess Margaret Cancer Center, Toronto, CA, ¹⁰AMGEN (Headquarters) - USA, Thousand Oaks, US, ¹¹The University of Texas M. D. Anderson Cancer Center, Houston, US

19:21 - 19:26 **84MO - A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01**

T. Yoshino¹, S. Siena², M. Di Bartolomeo³, K. Raghav⁴, T. Masuishi⁵, F. Loupakis⁶, H. Kawakami⁷, K. Yamaguchi⁸, T. Nishina⁹, M. Fakih¹⁰, E. Elez¹¹, J. Rodriguez¹², F. Ciardiello¹³, K. Saxena¹⁴, E. Yamamoto¹⁵, K. Kobayashi¹⁴, E. Bako¹⁴, Y. Okuda¹⁵, A. Grothey¹⁶, ¹National Cancer Center Hospital East, Kashiwa, JP, ²ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁴The M. D. Anderson Cancer Center, Houston, US, ⁵Aichi Cancer Center Hospital, Aichi, Japan, Nagoya, JP, ⁶IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁷Kindai University - Faculty of Medicine, Osaka, JP, ⁸Cancer Institute Hospital of JFCR, Tokyo, JP, ⁹Shikoku Cancer Center, Matsuyama, JP, ¹⁰City of Hope, Duarte, US, ¹¹Hospital Universitari Vall d'Hebron, Barcelona, ES, ¹²Clínica Universidad de Navarra, University of Navarra, Navarra, ES, ¹³Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ¹⁴Daiichi Sankyo Inc., NJ, US, ¹⁵Daiichi Sankyo Co., Ltd., Shinagawa, JP, ¹⁶West Cancer Center, Germantown, US

19:26 - 19:31 **85MO - Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)**

C.-F. Chiu¹, Y.-M. Yeh², K.-H. Yeh³, J. Desai⁴, T. Price⁵, N. Tebbutt⁶, J. Tabernero⁷, L. Velez⁷, T. Trevino⁸, A. Grothey⁹, R. Yaeger¹⁰, A. Gollerkeri¹¹, K. Maharry¹², S. Kopetz¹³, ¹China Medical University Hospital, Taichung City, TW, ²NCKUH - National Cheng Kung University Hospital, Tainan City, TW, ³National Taiwan University Hospital, New Taipei city, TW, ⁴Peter MacCallum Cancer Centre, Melbourne, AU, ⁵The Queen Elizabeth Hospital - Emergency Department, Woodville, AU, ⁶Darebin Street Specialist Medical Centre, Heidelberg, AU, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸University of Texas, Houston, US, ⁹West Cancer Center, Germantown, US, ¹⁰Memorial Sloan Kettering Cancer Center, New York, US, ¹¹Array BioPharma Inc. - Clinical Operations, Cambridge, Cambridge, US, ¹²Array BioPharma Inc., Cambridge, US, ¹³The University of Texas M. D. Anderson Cancer Center, Houston, US



19:31 - 19:39 **Invited Discussant abstracts 83MO, 84MO and 85MO**

J. Taieb, Hopital European George Pompidou, Paris, FR

19:39 - 19:47 **LIVE Q&A**



18:45 - 19:40 **Type: Mini Oral session** **Channel 2**
Title: Mini oral session on Genitourinary tumours
 Chair: Bertrand Tombal, BE

18:45 - 18:50 **218MO - Comparison of a 22-gene genomic classifier (GC) with NCCN for risk stratification of Asian prostate cancers (PCa)**
W. Wai Yee¹, A. Sim¹, K.P. Low², A. Meng¹, J. Tan¹, J.K.L. Tuan¹, T. Tan¹, M.L.C. Wang¹, L.S. Lee³, K.-J. Tay³, C.W.S. Cheng³, C.S. Tan⁴, L.Y. Khor³, J. Yeong³, E. Davicioni⁵, M.L.K. Chua¹, ¹NCCS - National Cancer Centre Singapore, Singapore, SG, ²National Cancer Centre Singapore, Singapore, SG, ³Singapore General Hospital, Singapore, SG, ⁴Changi General Hospital, Singapore, SG, ⁵Decipher Biosciences, San Diego, US

18:50 - 18:55 **219MO - Real-world utilization pattern of bone-targeted agents for metastatic prostate cancer: Web-based questionnaire study by Hong Kong Society of Uro-Oncology (HKSUO)**
D. Poon¹, K. Chan², T. Chan³, F.Y. Cheung⁴, M. Lam³, D. Lam⁵, K. Law⁶, A. Leung⁷, C. Lee⁸, K.C. Lee⁹, H. Sze¹⁰, K. Wong¹, C.C. Tong¹¹, W.K. Kwong¹², ¹The Chinese University of Hong Kong, Hong Kong, HK, ²Pamela Youde Nethersole Eastern Hospital, Hong Kong, HK, ³Queen Elizabeth Hospital, Hong Kong, HK, ⁴HKIOC - Hong Kong Integrated Oncology Centre, Hong Kong, HK, ⁵State Key Laboratory of Translational Oncology, Sir YK Pao Cancer Center, Hong Kong Cancer Institute, Prince of Wales Hospital, Hong Kong, HK, ⁶Princess Margaret Hospital, Hong Kong, HK, ⁷AMO Oncology Centre, Hong Kong, HK, ⁸International Medical Centre, Hong Kong, HK, ⁹Tuen Mun Hospital, Hong Kong, HK, ¹⁰HEAL Oncology, Hong Kong, HK, ¹¹Queen Mary Hospital, Hong Kong, HK, ¹²HK IOC - Hong Kong Integrated Oncology Center, Hong Kong, HK

18:55 - 19:01 **Invited Discussant abstracts 218MO and 219MO**
B. Tombal, Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE

19:01 - 19:09 **LIVE Q&A**

19:09 - 19:14 **202MO - Real-world outcomes of non-clear cell renal cell carcinoma: Retrospective study from tertiary cancer center in India**
A. Choudhary¹, A. Joshi², V. Noronha³, N. Menon², A. Kapoor², S. Menon³, K. Prabhaskar³, ¹Tata Memorial Hospital - Parel, Mumbai, IN, ²Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, ³Tata Memorial Hospital, Mumbai, IN

19:14 - 19:20 **Invited Discussant abstracts 201MO and 202MO**
T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

19:20 - 19:28 **LIVE Q&A**

18:45 - 20:00 **Type: Mini Oral session** **Channel 3**
Title: Mini oral session on Supportive and palliative care



Chair: Cheung Yin Ting, HK

- 18:45 - 18:50 **332MO - Comparison of NEPA-based versus olanzapine/aprepitant-based antiemetic regimen for Chinese breast cancer patients undergoing highly emetogenic chemotherapy**
W. Yeo¹, C. Yip², T. Lau², K. Lai², V. Chan³, L. Li³, E. Pang², M. Cheung², C. Kwok⁴, V. Chan², F. Mo², ¹The Chinese University of Hong Kong, Shatin, HK, ²The Chinese University of Hong Kong, Hong Kong, HK, ³Prince of Wales Hospital, Hong Kong, HK, ⁴Princess Margaret Hospital, Hong Kong, HK
- 18:50 - 18:55 **333MO - Cost-utility analysis of olanzapine in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy**
Y. Kondo, T. Sakakibara, M. Furuta, J. Kato, A. Kato, S. Mase, H. Sasaki, Y. Miyake, Toyota Kosei Hospital, Toyota, JP
- 18:55 - 19:01 **Invited Discussant abstracts 332MO and 333MO**
M. Sae-Teaw, Ubon Ratchathani University, Ubon Ratchathani, TH
- 19:01 - 19:09 **LIVE Q&A**
- 19:09 - 19:14 **290MO - Patient controlled analgesia (PCA) versus non-pca intravenous hydromorphone for severe cancer pain: Update from a multi-center, phase III randomized trial, HMORCT09-1**
R. Lin¹, S. Lin², J. Zhu³, S. Feng⁴, Q. Wu⁵, J. Fu⁶, F. Wang⁷, H. Li⁸, X. Li³, G. Zhang⁹, Y. Yao¹⁰, M. Xin¹¹, T. Lai¹², X. Lv¹³, Y. Chen⁸, Y. Lin¹³, L. Hong¹⁴, S. Lin¹⁵, S. Zhao⁸, C. Huang⁸, ¹Fujian Provincial Tumor Hospital, Fuzhou, CN, ²Mindong Hospital of Ningde City, Ningde, CN, ³Quanzhou First Hospital, Quanzhou, CN, ⁴Xiamen Haicang Hospital, Xiamen, CN, ⁵Guangqian Hospital of Quanzhou City, Quanzhou, CN, ⁶Xiamen Fifth Hospital, Xiamen, CN, ⁷Longyan Hospital of Traditional Chinese Medicine, Longyan, CN, ⁸Fujian Cancer Hospital, Fuzhou, CN, ⁹Shouning County Hospital, Ningde, CN, ¹⁰Putian People Hospital, Putian, CN, ¹¹Fujian Armed Police Corps Hospital, Fuzhou, CN, ¹²Longyan Boai Hospital, Longyan, CN, ¹³Xiamen Humanity Hospital, Xiamen, CN, ¹⁴Hanjiang Hospital of Putian City, Putian, CN, ¹⁵Fujian Medical University, Fuzhou, CN
- 19:14 - 19:19 **334MO - Haemoglobin, body mass index and age as risk-factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy**
D. Mizrahi¹, S. Park², T. Li², H. Timmins², T. Trinh³, K. Au³, E. Battaglini³, D. Wyld⁴, R. Henderson⁴, P. Grimison⁵, H. Ke⁵, J. Marker⁶, B. Wall⁶, D. Goldstein³, ¹St George Hospital and UNSW, Kogarah, AU, ²The University of Sydney, Sydney, AU, ³UNSW, Sydney, AU, ⁴Royal Brisbane and Women's Hospital, Brisbane, AU, ⁵Chris O'Brien Lifeshouse, Sydney, AU, ⁶The Australasian Gastro-Intestinal Trials Group, Sydney, AU
- 19:19 - 19:25 **Invited Discussant abstracts 290MO and 334MO**
K. Alexander, Queensland University of Technology, Brisbane, AU
- 19:25 - 19:33 **LIVE Q&A**



- 19:33 - 19:38 **335MO - Intervention combining nurse navigators (NNs) and a mobile application vs standard of care (SOC) in neuro-oncology patients (pts) treated with oral anticancer agents (OAA): A subgroup analysis of CAPRI, a single-center, randomized phase III trial**
A. Duflot-Boukobza¹, D. Mathivon¹, J. Legendre¹, M. Khettab¹, S. Oinino¹, M. Ferrua¹, A. Fourcade¹, N. Lezghed¹, F. Dhermain¹, F. Lemare¹, M. Guillet¹, V. Puglisi¹, M. Abbas¹, M. Pons¹, M. Di Palma¹, E. Minvielle², O. Mir³, S. Dumont¹, ¹Gustave Roussy Cancer Institute, Villejuif, FR, ²Ecole Polytechnique, Palaiseau, FR, ³Institut Gustave Roussy, Villejuif, FR
- 19:38 - 19:43 **291MO - Coping strategies and performance status among patients with advanced cancer in Indonesia**
N. Huda¹, H. Chang², ¹University of Riau, Pekanbaru, ID, ²Taipei Medical University, Taipei, TW
- 19:43 - 19:49 **Invited Discussant abstracts 335MO and 291MO**
C.L. Wong, The Chinese University of Hong Kong - The Nethersole School of Nursing, Sha Tin, HK
- 19:49 - 19:57 **LIVE Q&A**
- 18:45 - 19:40 Type: Mini Oral session Channel 4**
Title: Mini oral session on Gynaecological tumours
 Chair: Isabelle Ray-Coquard, FR
- 18:45 - 18:50 **239MO - NUWA Project: the first national real-world gynecological oncology research and patient management platform in China**
Q. Gao¹, D. Ma², Q. Zhou³, L. Wang⁴, Q. Li⁵, L. Chen⁶, J. Wang⁷, B. Xia⁸, W. Jiang⁸, S. Yao⁹, Y. Chen¹⁰, X. Xie¹¹, S. Zeng², X. Peng¹², ¹Tongji Hospital, Huazhong University of Science and Technology, Wuhan, CN, ²Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ³Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, CN, ⁴Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁵Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academic of Medicine Science, Jinan, CN, ⁶Tongji Hospital, Huazhong University of Science and Technology, Jinan, CN, ⁷Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ⁸Anhui Provincial Cancer Hospital, Hefei, CN, ⁹The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, ¹⁰The First Hospital Affiliated to Suzhou University, Suzhou, CN, ¹¹Women's Hospital, School of Medicine, Zhejiang University, Zhejiang, CN, ¹²Linkdoc Technology Co, Ltd, Beijing, CN
- 18:50 - 18:55 **240MO - Disparities in the radiotherapy management of cervical carcinoma across the globe-DOES THE INCIDENCE PATTERN MATCH THE INFRASTRUCTURE AVAILABILITY?**



S. Krithikaa¹, R. Lohith², K. Varun², S. Priya², S. Siyus², ¹HCG HealthCare Global Enterprises Ltd, Bangalore, IN, ²HCG HealthCare Global Enterprises Ltd, Bengaluru, IN

- 18:55 - 19:01 **Invited Discussant abstracts 239MO and 240MO**
P. Khaw, Peter MacCallum Cancer Centre, Melbourne, AU
- 19:01 - 19:09 **LIVE Q&A**
- 19:09 - 19:14 **241MO - Survival impact of pretreatment absolute lymphocyte count in cervical cancer patients receiving definitive chemoradiation**
Y.H.E. Chuk¹, S.W.S. Tse¹, C.Y.R. Ho¹, H.Y. Wong¹, N.Y. Yeung¹, K.M. Cheung¹, J.C.H. Chow¹, K.H. Wong², ¹Queen Elizabeth Hospital, Kowloon, HK, ²Queen Elizabeth Hospital, Hong Kong, HK
- 19:14 - 19:19 **242MO - Sarcopenia as A Predictor of Overall Survival in Patients with Ovarian Cancer Undergoing Chemotherapy : A Systematic Review and Meta-Analysis**
V. Damay¹, F. Kwenandar¹, K. Japar², T. Hariyanto², P. Wibisono³, A. Kurniawan⁴, ¹UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, ²Faculty of Medicine Pelita Harapan University, Tangerang, ID, ³University of Pelita Harapan, Tangerang, ID, ⁴Faculty of Medicine, Pelita Harapan University, Tangerang, ID
- 19:19 - 19:25 **Invited Discussant abstracts 241MO and 242MO**
D.S. Tan, NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG
- 19:25 - 19:33 **LIVE Q&A**



18:45 - 20:00	Type: Young Oncologist session Title: Clinical cases discussion 2	Channel 5
Chair: Claudia Cardone, IT; Christoph Oing, DE		
18:45 - 18:50	YO6 - Rechallenge with Ipilimumab plus Nivolumab after progression on anti-PD1 in MSI-H colorectal cancer: A Case Report.	
	<u>C. Andrade</u> ¹ , M. Cesca ¹ , T. Felismino ² , ¹ A.C. Camargo Cancer Center - Fundacao Antonio Prudente, Sao Paulo, BR, ² A.C. Camargo Cancer Center - Fundacao Antonio Prudente, São Paulo, BR	
18:50 - 18:55	YO24 - Novel germline MLH1 gene variant in a family with Muir-Torre Syndrome	
	<u>M. Pagliuca</u> ¹ , F. Napolitano ² , C. Condello ² , M. Giuliano ² , L. Formisano ² , A. Verrazzo ² , P. De Placido ² , L. Bencivenga ² , S. De Placido ² , C. De Angelis ² , ¹ Azienda Ospedaliera Universitaria Federico II, Napoli, IT, ² University of Naples "Federico II", Napoli, IT	
18:55 - 19:00	YO25 - Hypomagnesaemia in Gitelman syndrome as a “second-hit” leading to multiple neoplasia in the setting of germline monoallelic MUTYH mutation	
	<u>J.Y. Chan</u> ¹ , M.R. Toh ¹ , S.T. Chong ¹ , N.D.B. Ishak ¹ , S.H. Chan ¹ , A. Boot ² , Y. Chen ¹ , S.-T. Li ¹ , M.-H. Chew ³ , J. Ngeow ⁴ , ¹ National Cancer Center Singapore, Singapore, SG, ² Duke-NUS Medical School, Singapore, SG, ³ Sengkang Health, Singapore, SG, ⁴ Cleveland Clinic, Cleveland, US	
19:00 - 19:10	Live Q&A and live discussion	
	<u>C. Cardone</u> , Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT	
19:10 - 19:15	YO12 - Does a recurrent, non metastatic paraganglioma of urinary bladder require radical surgical extirpation - A Young oncologist case report.	
	<u>R. D. Arora</u> , All India Institute of Medical Sciences, Delhi, IN	
19:15 - 19:20	YO22 - ROS1-rearranged non-small cell lung cancer (NSCLC) with secondary resistance mutation: A report of L2026M in vivo and clinical activity of Cabozantinib	
	<u>C. De Liz</u> , L.B. Mendes Gomes, H. Carioca Freitas, D. Carraro, G. Tardin Torrezan, A.C. Camargo Cancer Center - Fundacao Antonio Prudente, Sao Paulo, BR	
19:20 - 19:30	Live Q&A and live discussion	
	<u>C. Oing</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	



20:30 - 22:00 **Type: Special Session** **Channel 1**
Title: Joint SITC-ESMO Immunotherapy Primer 3
 Chair: Han Chong Toh, SG

20:30 - 20:50 **CAR T-cell therapies for blood cancer: Off to a flying start, the road ahead and what's on the horizon**
M. Daher, The University of Texas MD Anderson Cancer Center, Houston, US

20:50 - 21:10 **Driving immune cells into the clinic without a CAR - Including other forms of T-cell, NK cell therapies**
F. Lim, SGH-Singapore General Hospital/Singhealth-Academia, Singapore, SG

21:10 - 21:30 **Cancer vaccines yesterday, today, and tomorrow: Cinderella no more?**
B.A. Fox, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US

21:30 - 22:00 **Live Q&A and live discussion**